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7SUMMARY
Main Findings 
1. National policies and context 
The United Kingdom (UK) Drug Strategy was updated in December 2002. There is a
particular focus on Class A drugs and there is a renewed emphasis on reducing drug-
related harm and helping drug users access treatment, including through the criminal
justice system.
The year 2003 saw changes in legislation, as well as new legislation including: 
• cannabinol and its derivatives (previously Class A), and cannabis (previously 
Class B) have been reclassified as Class C drugs;
• GHB has been classified as a Class C drug;
• legislation allows the provision of injecting paraphernalia (other than needles and 
syringes) by health service providers to reduce the sharing of such 
equipment, and therefore, the transmission of infection;
• the Anti-Social Behaviour Act 2003 introduces provisions to assist in closing crack 
houses; and
• the Proceeds of Crime Act 2002 and the Money Laundering Regulations 2003
implement the Second EU Money Laundering Directive. The Assets Recovery 
Agency also became operational.
Direct expenditure for tackling drugs in the 2003/04 financial year was £1,244 million
(€17661 million); this was made up of:
• protecting young people £149 million (€211.5 million);
• safeguarding communities £212 million (€301 million);
• drug treatment £503 million (€714.2 million); and
• reducing supply £380 million (€539.6 million).
2. Drug use in the population
Prevalence in the general population of use of any illegal drug remains stable with
lifetime prevalence being over a third, and between seven and 12 per cent of adults
having used drugs in the last year. 
Young adults under 30 continue to be significantly more likely to use illicit drugs; lifetime
prevalence is around 50 per cent. However, throughout most of the UK, the gradual
decline in prevalence amongst 16 to 24 year olds continues.
Prevalence amongst school children (11 to 16 year olds) is stabilising with last year
prevalence of any illicit drug at around 25 per cent. 
However, prevalence continues to be particularly high amongst vulnerable young
people.
Males are over twice as likely to use drugs; although this gender difference is less
marked amongst those in their teens. Drug use is greatest amongst the white
population, irrespective of age. 
1 All conversions used in this report will use the exchange rate of £1 equals €1.42 as of May 2003 unless otherwise
stated.
Cannabis continues to be the most commonly used drug across the general and school-
aged population. Prevalence of all other drugs remains low, although there has been an
increase in the use of crack, cocaine and ecstasy. 
Although some sources suggest a rise in the use of magic mushrooms and an interest
in licit ‘herbal highs’, such as types of salvia; this is yet to be confirmed.
3. Prevention 
Drug education is a key component of UK Drug Strategy; guidance for schools has
been, or is being, developed throughout the UK. 
Vulnerable young people are targeted through a number of specialist interventions.
A National Collaborating Centre for Drug Prevention has been established.
National public information campaigns, as part of the action to reduce the use of Class
A drugs, have been launched throughout the UK.
4. Problem drug use 
Latest UK estimates of problem drug use are 9.35 per thousand of the population aged
15 to 64 years (360,811) and for injecting drug use, 3.2 per thousand (123,498). Males
continue to represent over 70 per cent of new presentations to treatment. Opiates
continue to be the most commonly used drug by those seeking treatment (80%). There
is some evidence of an increase in the number of individuals presenting for treatment
whose main drug of use is crack or cocaine, but it remains low (4% to 6%). 
5. Treatment 
Treatment provision has increased substantially, and standards and national guidance
have been introduced. Most treatment continues to be through specialist drug services
(outpatients) with increasing GP involvement. Medically assisted methadone
maintenance is the preferred treatment, with still low, but increasing, use of
buprenorphine (see 11). Services for crack users are being piloted. Referral into
treatment through the criminal justice system is a key component of UK Drug Strategy
(see 12).
6. Health correlates and consequences
The number of drug-related deaths continues to fall from its peak in 2000, as does
average age of death. Opiates continue to account for a large majority of deaths. While
still rare, cocaine deaths have been rising since 2000. Deaths involving ecstasy and
volatile substances are relatively unchanged in recent years. The decline in the number
of deaths due to HIV contracted through injecting drug use has levelled off.
Prevalence of HIV amongst injecting drug users remains at less than or around one per
cent. Incidence of hepatitis C (HCV) continues to increase; current prevalence is
approximately 40 per cent. Prevalence of hepatitis B (HBV) has levelled off at 20 per
cent. Outbreaks of hepatitis A and other infections are increasing.
Information from Scotland suggests pregnancies involving women who use drugs have
risen.
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7. Responses to health correlates and consequences
Prevention of drug-related deaths
UK Strategy is to reduce drug-related deaths by 20 per cent from 1999 to 2004, to be
achieved through information campaigns, treatment initiatives, and better surveillance,
monitoring and research. 
Prison services are developing interventions to reduce the risk of fatal overdose upon
release from custody.
To reduce deaths from volatile substances there are a number of awareness campaigns
aimed at parents and at retailers. The Department of Health is drafting an action plan on
volatile substance abuse.
Prevention and treatment of drug-related infectious diseases
The Hepatitis C Action Plan for England was launched in June 2004 prioritising the
prevention of infection and disease progression. An action plan for Scotland is due in
autumn 2004. A range of services to promote the uptake of HCV testing has been
funded. Legislation allowing for the provision of injecting paraphernalia aims to reduce
the spread of infections by reducing sharing.
Interventions related to psychiatric comorbidity
The Scottish Executive plans to improve education and awareness, and is looking
towards more effective planning, delivery of care and treatment services.
Interventions related to other health correlates and consequences
The Scottish Executive is implementing recommendations to make services more
flexible, accessible and appropriate in meeting the needs of pregnant drug users and
the children of drug users.
The Home Office has developed a toolkit on drugs and driving; information campaigns
are to begin in England, Wales and Scotland, including a website aimed at young
people. 
8. Social correlates and consequences
There was a 10 per cent rise in drug offences. However, numbers found guilty of
unlawful supply of heroin are stable and the number convicted for unlawful supply fell
by less than one per cent in 2003. 
Newly published research evidence suggests that there is a strong association between
drug use and offending, 69 per cent of arrestees tested positive for drugs. 
A programme has been established to improve measures of drug-related crime. A new
continuous arrest survey began in 2003. 
It is suggested that over half those entering custody in England and Wales and two
thirds in Scotland are problem drug users.
9. Responses to social correlates and consequences
The Supporting People Programme was introduced in 2003, funding supported
accommodation for marginalised groups (not only drug users). Progress2work,
supporting drug users into employment, will be initiated in all areas during 2004. 
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Healthcare services in all non-private prisons in England will become part of the
National Health Service by 2006. Clinical services (detoxification and maintenance-
prescribing programmes) remain available in all local and remand prisons. Programmes
for drug users continue to expand and include intensive drug rehabilitation programmes,
therapeutic communities, withdrawal management units, and low-intensity short
duration programmes. 
The Drugs Intervention Programme (DIP)2 was launched in 2003 with the aim of more
effectively channelling problem drug users, particularly persistent offenders, from the
criminal justice system into treatment.
All Youth Offending Teams, from April 2004, must ensure young offenders are screened
for substance use.
The Railways and Transport Safety Act 2003 gives police the power to undertake
preliminary tests of impairment and screening for drugs at the roadside.
10. Drug markets
Overall, seizures have continued to rise since 2000, especially for cannabis and crack.
Seizures of amphetamines have stabilised. 
The prices of all substances have continued to fall. The purity of brown heroin and
amphetamines fell, cocaine purity has risen and that of crack has stayed the same in
comparison to 2002.
Selected issues
11. Buprenorphine, treatment, misuse and prescription practices
Buprenorphine, under the brand name Subutex, was licensed for use for the
management of drug dependence in the UK in 1999, although restricted to Schedule
three. No other product containing buprenorphine is licensed for the management of
opiate dependence.
Clinical guidelines provide an outline of indications, contraindications and precautions,
dosage regimens, maintenance treatment and prescribing, detoxification and shared care.
Since 2001, there has been a considerable increase in the use of buprenorphine,
indicated by in the number of prescribed items: from 5,000 in 1999 to 310,000 in 2003. 
Research and reviews suggest buprenorphine and methadone are of similar efficacy in
retaining clients in treatment and reducing heroin use.
In the late 1980s and early 1990s, a wave of buprenorphine misuse (Temgesic), in the
form of injecting, was reported in several parts of the UK. Reporting of abuse of
buprenorphine is not routinely undertaken.
12. Alternatives to prison targeting to drug-using offenders
In the UK, drug treatment cannot be strictly defined as an alternative to custody; if a
custodial sentence is required, offenders will enter custody. However a key component
of national drug policy is to increase the number of drug-using offenders in treatment.
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2 The Drugs Intervention Programme was originally launched as the Criminal Justice Interventions Programme but was
re-named in October 2004.
There are a number of interventions aimed at this population. For those in police
custody, these include help with referral into treatment for arrestees (Arrest Referral),
drug testing on charge, and Conditional Cautioning. Arrest Referral and testing on
charge is being piloted for those under the age of 18 years. A restriction on bail pilot was
also introduced in 2004 giving new powers to courts to order drug treatment and
assessment as conditions of bail.
There are presently a number of community sentencing options many of which include
a commitment to undergo treatment.
The Drugs Intervention Programme seeks to develop and integrate measures for
directing adult drug-using offenders out of crime and into treatment, taking advantage of
all opportunities within the criminal justice system (police custody, the courts, probation
and prison).
13. Public nuisance definitions, trends in policies, legal issues and intervention
strategies
Surveys on crime and policing in the UK show that the public place a high priority on
tackling incidents described as anti-social behaviour, minor disorder or ‘quality of life
issues’. These include using and selling drugs.
The Drugs Strategy Directorate works with the Anti-Social Behaviour Unit to tackle drug-
related anti-social behaviour and public nuisance. Measures target street drug taking,
using drugs in public, discarded needles, public intoxication as well as begging, rough
sleeping and sex work. They also target street drug dealing and the problems
associated with property used for the sale of drugs such as crack (crack houses).
The Home Office has published a number of guidance manuals for local partnerships
who are charged with managing such issues.
A new Police Plan defines the way that police forces should take account of drug-related
nuisance.
The Anti-Social Behaviour Act 2003 is designed to tackle the serious nuisance
associated with properties used for the sale and use of crack and other drugs.
Most relevant developments and trends:
• The reclassification of cannabis.
• The implementation of the Proceeds of Crime Act 2003 and the accompanying 
Assets Recovery Agency, to prevent money laundering.
• The Anti-Social Behaviour Act 2003 introduced provision to assist in tackling the 
public nuisance issue of property used for the sale of drugs such as crack (crack
houses).
• Prevention remains high on the agenda with new guidance for schools, continued 
emphasis on prevention activities outside school for vulnerable young people, and 
the establishment of the National Collaborating Centre for Drug Prevention. 
• Prevalence in the general adult population of use of any illegal drug remains 
stable, and there are indications of a decrease in prevalence amongst those aged 
16 to 24 years. Prevalence amongst 11 to 16 year olds of use of any illegal drug, 
which doubled over the last decade, is stabilising.
• Nevertheless, there are indications of a continued increase in cocaine use, 
accompanied by a rise in the mention of cocaine in deaths and a rise in cocaine 
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drug offences. Continued increase in the use of crack has also been accompanied 
by a rise in possession offences. There are also increasing indications of an 
increase in the use of magic mushrooms. 
• There are indications that the incidence of hepatitis C continues to increase.
• Treatment provision has increased substantially, with the Drugs Intervention 
Programme designed to increase the number of offenders in treatment and other 
services. 
• The use of buprenorphine is steadily increasing for the treatment of drug use.
Overall analyses and interpretation of development and trends 
While drug use, on the whole, is stabilising there are indications of a rise in Class A drug
use: cocaine, crack, ecstasy and, possibly, magic mushrooms. It is however of note that
this increase is based on information about prevalence obtained prior to the Updated
Drug Strategy with its emphasis on reducing Class A drug use. Evidence of the
effectiveness of this will not be available for some time. 
The reclassification of cannabis, undertaken as part of the emphasis placed on Class A
drugs, is an important development in the UK. Its impacts, however, are yet to be
evaluated.
With prevalence estimates of problem drug use being rarely undertaken, it is difficult to
accurately gauge any changes.
Consistency between indicators 
Seizures of drugs, on the whole, had begun to decrease since the late 1990s, but are
now rising, including those for cannabis, the most seized drug (and most used drug),
crack and benzodiazepines. The continued increase in cocaine use, within the general
population and amongst problem users, has been accompanied by a rise in mentions of
cocaine in deaths and a rise in drug offences for cocaine, although seizures of cocaine
have fallen overall since 2000. Indications of increases in crack use have been
accompanied by an increasing public nuisance problem of property used for the sale of
crack (and other Class A drugs); it is of note that there has been an increase in crack
seizures and of offences for possession with intent to supply crack. 
The decrease in seizures of LSD, and the stabilisation in seizures of amphetamines are
reflected in the decrease of their use in the general population. Reduced seizures of
ecstasy may reflect its stabilisation in terms of use.
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PART A: NEW DEVELOPMENTS AND TRENDS
1. National policies and context
1.1 Overview
The Misuse of Drugs Act 1971 is the foremost piece of drug legislation in the UK,
dividing controlled drugs into three classifications (A, B and C) depending on their
potential for harm. These classifications correspond to a graded scale of penalties for
possession and supply, with Class A drugs carrying the highest penalties. Use of
controlled drugs per se is not an offence in the UK; however, since 1995, it has been
contrary to prison rules (HM Prison Service 1995; HM Prison Service 2004a).
The UK population is 58.8 million, spread across the four administrations (2001 census).
Eighty-four per cent (49 million) live in England, 8.6 per cent (5 million) in Scotland, 4.9
per cent (2.9 million) in Wales and three per cent (1.7 million) in Northern Ireland3. Since
1999, a number of institutions have been devolved to the administrations of Northern
Ireland, Scotland and Wales; each has its own parliament or assembly, which have
responsibilities for health, education and some criminal justice functions.
There is, however, a UK Drug Strategy, Tackling drugs together to build a better Britain,
launched in 1998 (UKADCU 1998) and updated in 2002 (Drugs Strategy Directorate
2002a). The Strategy seeks to balance the needs of individual users with those of the
wider community. There are four principal aims: prevention of drug use amongst young
people, safeguarding communities, the provision of treatment and reducing availability.
These are to be achieved through education, prevention programmes, expanded
treatment and legal sanctions. The devolved authorities in Northern Ireland, Scotland
and Wales have developed their own strategies that reflect the aims of the UK Strategy,
but include specific objectives and priorities tailored to their individual circumstances.
Tackling drugs in Scotland: action in partnership (Scottish Office 1999) and the Drug
strategy for Northern Ireland (Northern Ireland Office 1999) were launched in 1999
(since 2000 the Department of Health, Social Services and Public Safety (DHSSPSNI)
has taken lead responsibility), and Tackling substance misuse in Wales: a partnership
approach (National Assembly for Wales 2000) was launched in 2000, the latter also
including alcohol and solvent misuse.
Delivering the Strategy is a cross-government initiative. Since 2001, the Home
Secretary has taken lead responsibility as Chair of the Cabinet Ministerial Sub-
Committee on Drugs Policy; this committee includes ministers from the Department of
Health, the Department for Education and Skills, the Office of the Deputy Prime Minister,
the Cabinet Office, the Treasury and the Foreign and Commonwealth Office. The Drug
Strategy Delivery Group supports this structure at civil service senior official level.
Membership reflects that of the Cabinet Sub-Committee, with additional members
drawn from the devolved administrations, the English regions and departments and
agencies responsible for delivery. In addition, there are cross-departmental groups
focusing on individual strategy aims; for example, the Concerted Inter-departmental
Action Group (chaired by HM Customs and Excise) reviews supply reduction. These
delivery groups include representatives from a wide range of agencies and
stakeholders. 
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3 For more information on the results from England and Wales census, please see
www.statistics.gov.uk/census2001/profiles/uk.asp. For Northern Ireland, please see www.nicencus2001.gov.uk and for
Scotland, please refer to www.scrol.gov.uk.
The Drugs Strategy Directorate of the Home Office is responsible for co-ordinating the
Drug Strategy and ensuring its delivery. In England, delivery is through nine regional
Government Offices, who support and monitor the work of the 149 local drug
partnerships. Drug (and Alcohol) Action Teams (D(A)ATs) bring together local agencies
involved in tackling the use of drugs, including health and local authorities, police,
probation, social services, education, youth and voluntary services. Crime and Disorder
Reduction Partnerships in England and Community Safety Partnerships in Wales work
with the police and communities to tackle local drug problems and associated crime. It
is of note that in Wales, in 2003, D(A)ATs4 were disbanded and in each of the four police
authority areas, Regional Advisory Teams were put in place; the 22 Community Safety
Partnerships were asked to establish Local Substance Misuse Action Teams to
undertake executive actions on behalf of their respective partnerships. In Northern
Ireland, a Regional Drug and Alcohol Strategy Co-ordinator is responsible for driving
forward delivery across eight government departments, agencies and the voluntary and
community sector. Four Drug and Alcohol Co-ordination Teams bring together local
agencies involved in tackling the use of drugs, including services similar to those
involved in England.
Representation of the Drug Strategy and its delivery has been generally positive in the
media (IMPACON 2003), although there is widespread public concern about drug-
related crime and its effects on communities (Fraser 2002; Simmons and Dodd 2003).
As such, drugs still retain a high profile and remain a controversial topic.
1.2 Legal framework 
1.2.1 Reclassification of cannabis 
The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 20035 reclassified
cannabinol and cannabinol derivatives (previously Class A drugs), and cannabis and
cannabis resin (previously Class B) as Class C drugs; effective from January 2004. This
followed an assessment of their relative harmfulness (ACMD 2002), and should enable
a more effective message to be conveyed about the graded scale of danger of different
types of drugs, according to their classification. In addition, it reinforces Government’s
priority to tackle those drugs that cause the most harm: Class A drugs.
With reclassification, the maximum sentence for possession has been reduced from five
to two years imprisonment. However, penalties for drug-related offences have been
increased; the maximum penalty for trafficking Class C drugs has been increased from
five to 14 years imprisonment. Under the Cannabis Enforcement Guidance issued by
the Association of Chief Police Officers (ACPO) to police forces in September 2003,
there is a presumption against arrest for those aged 18 or over found in possession of
cannabis6 (ACPO 2003). Guidance is directed at ensuring that individual offenders are
dealt with appropriately, with advice specifically addressing:
• those repeatedly dealt with for possession of cannabis (repeat offenders);
• those whose cannabis use causes or threatens to cause public disorder; and 
• those in possession of cannabis in or near premises where young people are  
present and vulnerable (e.g. schools, youth clubs and play areas).
4 In Wales local action teams have been concerned with alcohol since devolution. 
5 The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 can be found at http://www.legislation.hmso.gov.uk/acts.htm. 
6 Cannabis Enforcement Guidance can be found on
http://www.drugs.gov.uk/NationalStrategy/CannabisReclassification/ACPO/cannabisenforcementguidance-formal-
5sep03.doc.
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7 The Lord Advocate is the chief law officer of the crown who has ultimate responsibility for criminal prosecutions in
Scotland. The Lord Advocate does not usually act in inferior courts, where prosecution is carried out by Procurators
Fiscal acting under their instructions.
8 The Procurator Fiscal is an officer of the Scottish court who enquires into suspicious deaths and carries out the
preliminary questioning of witnesses to crime.
9 For more information, please see http://www.talktofrank.com.  
10 Please see http://www.knowthescore.info for more information.
11 For further information, see http://www.healthpromotionagency.org.uk.
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It is expected that for most possession offences, a police warning and confiscation of
the drug will be sufficient. The subsequent time saved is intended to allow the police to
focus greater resources on priority areas such as tackling Class A drug supply offences.
However, young people under 18 years in England and Wales arrested for cannabis
offences will continue to be dealt with under the provisions of the Crime and Disorder
Act 1998. Police enforcement will be consistent with the more structured framework for
early juvenile offending established under this Act: a young offender can receive a
reprimand, final warning or charge depending on the seriousness of the offence.
Following one reprimand, any offence will lead to a final warning or charge, and any
further offence will result in a charge. After a final warning, the young offender will be
referred to the Youth Offending Team (YOT) where their substance use will be
assessed, and arrangements will be made for treatment or other support as required. 
This reclassification has been dealt with in various ways by the different administrations.
In Northern Ireland, there are similar arrangements to those in England and Wales,
whereas in Scotland, ACPO guidance does not apply. Here, there are existing
conditional powers of arrest as prescribed by the Misuse of Drugs Act 1971 and the
Criminal Procedure (Scotland) Act 1995. These state that arrest for cannabis
possession is not automatic and depends on the individual circumstances. It is the
responsibility of the Lord Advocate7 to issue guidance to Scottish police forces, and the
Procurators Fiscal8 (rather than the police) to decide whether to institute criminal
proceedings. At present, police forces are not instructed to issue cautions to those in
possession of cannabis, and all cases are reported to Procurators Fiscal. 
The continuing illegal status and harmfulness of cannabis is being publicised through
the FRANK campaign9, and in Scotland, through the “Know the Score” Drugs
Communications Strategy campaigns10. In Northern Ireland, the Health Promotion
Agency is running similar campaigns11 (see Chapter 3).
1.2.2 Classification of GHB
Following a decision by the United Nations to add GHB (gamma hydroxybutyrate) to
Schedule IV of the 1971 Convention on Psychotropic Drugs, from July 2003 GHB
became a Class C controlled drug under the Misuse of Drugs Act 1971.
1.2.3 Supply of drug injecting paraphernalia
An amendment to the Misuse of Drugs Act 1971 came into force in August 2003 to allow
doctors, pharmacists and drug workers to legally supply swabs, sterile water, certain
mixing utensils (e.g. spoons, bowls, cups and dishes) and citric acid to drug users who
obtained controlled drugs without a prescription  (see UK Focal Point Report 2003). 
1.2.4 Anti-Social Behaviour Act 2003
The Anti-Social Behaviour Act 2003 introduced provisions to assist in closing crack-
houses (see Chapter 13).
1.2.5 Money laundering
The Proceeds of Crime Act 2002 and the Money Laundering Regulations 2003
implemented the Second EU Money Laundering Directive12. Laundering now relates to
the proceeds of any crime, as does the obligation on the regulated sector to report it.
The latter was extended from March 2004 to encompass not just financial institutions,
but also the “gatekeepers to the financial system” such as lawyers, accountants,
casinos, estate agents and certain dealers in High Value Goods. This reporting
obligation extends not just to actual suspicion or knowledge of money laundering, but
also to when there are reasonable grounds to know or suspect money laundering13.
Legislative change has been complemented by a review of the reporting system, and
substantial reforms have been made to improve the quality and speed of the
dissemination of the intelligence provided to law enforcement agencies by the National
Criminal Intelligence Service (NCIS). The Assets Recovery Agency also became
operational in February 200314.
1.3 Institutional framework, strategies and policies
1.3.1 Co-ordination arrangements
Each administration has, or is developing, its own performance management
arrangements. These will rationalise the bureaucratic burdens on local partnerships.
This reflects the central government principle of local responsibility for delivery, set in a
framework of national standards and supported by a strategic approach to performance
indicators. In England the nine Government Offices will be the key mechanism for
negotiating local priorities, targets and milestones with local partnerships, and for
monitoring progress against these.
1.3.2 National plan and/or strategies
There is no new information available for 2003. Please refer to Chapter 1.1 of this report
and UK Focal Point (2003) Chapter 1.1.
1.3.3 Implementation of policies and strategies
There are a number of new initiatives and programmes to facilitate the implementation
of UK Drug Strategy, such as the Drugs Intervention Programme15 (DIP - see Chapter
12). There have been a variety of guidelines and toolkits developed in 2003, for
example, helping to increase the number of those who are hard to reach accessing
treatment services. Local partnerships and agencies are charged with local
implementation, and to complement this, funding arrangements were rationalised in
many areas during 2003/04.
1.3.4 Impact of policies and strategies 
The impact of the Drug Strategy is measured predominantly by performance against
Public Service Agreements (PSAs)16. Current performance is shown in Table 1.
12 For more information, please see
http://europa.eu.int/comm/justice_home/fsj/crime/laundering/wai/fsj_crime_laundering_en.htm. 
13See http://www.renewal.net/Documents/RNET/Policy%20Guidance/Reportpateight.pdf. 
14 For more information, please see http://www.assetsrecovery.gov.uk .
15 The Drugs Intervention Programme was originally launched as the Criminal Justice Interventions Programme but
was re-named in October 2004.
16 These can be found on http://www.hm-treasury.gov.uk. 
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Table 1: The current status of the Public Service Agreements
1.4 Budget and public expenditure
1.4.1 In law enforcement, social and health care, research, international actions, co-
ordination, national strategies
Direct expenditure for tackling drugs in 2003/0418 was £1,244 million (€1,766 million), a
rise of £18 million (€25 million) from 2002/03 (Drugs Strategy Directorate 2002a). The
budget was then divided up to target specific areas in the Strategy (see Figure 1).
Public Service
Government 
Agreement
Department Performance
Responsible
To reduce the use of Home Office The use of Class A drugs among 
illicit drugs among all young people under 25 has been
young people under the broadly stable since 1996, with
age of 25 years. downward trends in some drugs 
such as ecstasy.
To reduce drug-related Home Office An interim proxy measure shows 
crime. a two per cent reduction in drug-
related acquisitive crime 
convictions for the year ending 
June 2003, from the previous 
year.
To reduce the availability HM Customs In the first nine months of 2003, 
of illegal drugs. and Excise 1.67 tonnes of heroin and 16.8 
tonnes of cocaine were taken out 
of the supply chain and 121 
significant trafficking groups were 
disrupted. Also, £19.7 million 
(€28 million)17 of drug-related 
criminal assets were confiscated.
To increase the number of Department of During 2002/03, there were of
problem drug users Health 140,900 drug users in treatment,
in drug treatment a 41 per cent increase since
programmes. 1998. Fifty seven per cent 
successfully completed or 
sustained treatment.
17 All conversions used in this report will use the exchange rate of £1 equals €1.42 as of May 2003 unless otherwise
stated.
18 This refers to the financial year from 1st April 2003 to 31st March 2004.
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Figure 1: Direct expenditure for tackling drugs in the United Kingdom
Source: Drugs Strategy Directorate 2002a.
1.4.2 Funding arrangements
The various funding streams from central Government departments to local
partnerships have also been rationalised into the pooled drug use treatment budget
(2001), the young people’s substance misuse pooled budget (2004) and the Building
Safer Communities Fund (2004).
1.5 Social and cultural context
1.5.1 Public opinion of drug issues
The associated campaigns following the reclassification of cannabis provided the ideal
opportunity to highlight its continuing illegal status and to inform the public of its related
harms. The effectiveness of such a campaign was evaluated by assessing the attitudes
of 14 to 17 year olds before the reclassification, then again after the reclassification and
the campaign (see Table 2). The findings will inform longer-term educational campaigns.
Table 2: Attitudes of 14 to 17 year olds regarding cannabis
Source: LVQ Research 2004.
Attitudes Pre-reclassification Post-reclassification 
and the campaign
Believe cannabis to be illegal 88% 93%
Believe smoking cannabis 
74% 81%could be harmful
Aware of a change in the law 38% 61%
Believe that under the new 24% of those  41% of those 
law you will always/are likely   aware of                        aware of
to be arrested if found in a change in a change in
possession of cannabis the law the law
Believe they would definitely 
or probably take cannabis if 17% 12%
offered
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1.5.2 Debates and initiatives in parliament and civil society
Debate concerning the legalisation of drugs continues, but this has been low key despite
a senior member of the North Wales police force stating that this could be a valid way
forward (Bunyan 2004).
1.5.3 Media representations
Media analysis reports suggest representation of the Government’s Drug Strategy has
been generally positive, particularly in respect to the expansion of DIP (see Chapter 12).
There has been widespread coverage of the reclassification of cannabis and the results
of the latest British Crime Survey (IMPACON 2003).
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2. Drug use in the population
2.1 Overview
• In the UK, the primary sources of information about prevalence of drug use 
amongst the adult population are from representative household surveys.
• In England and Wales, the British Crime Survey (BCS) questions respondents, 
aged 16 to 59, about a number of crime-related topics including their experience 
of illicit drugs19. Since 2002 it has become a continuous survey reporting quarterly.
• The Scottish Crime Survey (SCS) is undertaken less frequently, the latest survey
being in 2003 (although this has not yet been published, so the latest available
data are from 2000). The questions are comparable to those asked through the 
BCS.
• In Northern Ireland, a Drug Prevalence Survey, using the EMCDDA model 
questionnaire and recommended methodology, was conducted for the first time in 
2002/03 in association with the Republic of Ireland. This survey will be repeated in
2005/06 subject to funding.
Amongst the school age population, surveys of drug use prevalence are:
• in England, a survey of the prevalence of smoking, drinking and drug use amongst 
young people (11 to 15 year old school children), undertaken annually since 1998;
• the Young Person’s Behaviour and Attitudes Survey, which was undertaken in 
Northern Ireland in 2000 for the first time, repeated in 2003 and will run every three 
years thereafter; 
• in Scotland, the Scottish Schools Adolescent Lifestyle and Substance Use Survey
(SALSUS)20; and 
• the Health Behaviour in School Age Children Survey (HBSC), which provides 
Welsh data; this is undertaken every four years with a two-year interim survey. The 
most recent survey, the sixth in the series, was conducted in 2001/0221.
In addition, the European School Survey Project on Alcohol and Other Drugs (ESPAD)
surveys children aged 15 and 16 in a representative sample of private and state
secondary schools every four years. The survey was undertaken in 2003 but results
were not available for the UK at the time of publication.
While such surveys offer estimates of prevalence of illicit drug use in the general
population, they do not provide useful estimates of problem drug use; these are
provided in Chapter 4.
Prevalence of use of any drug has remained stable over the last few years (based on
last year prevalence), although use of Class A drugs is increasing (Fraser 2002; Condon
and Smith 2003; NACD and DAIRU 2003). Amongst adults, drug use is highest in
England and Wales where around a third have ever used. In Northern Ireland,
prevalence of drugs remained exceptionally low (House of Commons Northern Ireland
Affairs Committee 2003), with no definable drug culture until the 1990s. However, by
2003, one fifth (20%) of the adult population reported lifetime use (NACD and DAIRU
2003). Young adults under 30 are significantly more likely to use illegal drugs; in most
19 The BCS and SCS do not provide information on all the drugs asked for by the EMCDDA (that is alcohol, tobacco,
barbiturates and benzodiazepines).
20 In Scotland, a similar survey to England was run until 2002 when SALSUS was introduced.
21 England, Scotland and Northern Ireland have taken part in this survey until recently.
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of the UK lifetime prevalence for this age group is around 50 per cent (although it is 31%
in Northern Ireland for those aged 15 to 34 years). Throughout most of the UK, there
appears to have been a significant and gradual decline in the use of any drug amongst
16 to 24 year olds in the last five years (although use of Class A drugs in this age group
has remained stable since the late 1990s). Of note is that the age band with the highest
prevalence is widening as young people continue to use into their thirties.
Increase over time is most pronounced amongst school children. Data for England
suggest that over the last few years use of any illicit drug by 11 to 15 year olds has
nearly doubled to approximately 20 per cent. Much of this may be due to the change in
the question format of the survey in 2001, which resulted in a higher proportion of pupils
reporting that they had ‘tried sniffing glue, gas, aerosols or solvents’ compared with
previous surveys. Therefore, estimates of taking drugs from 2001 onwards are not
strictly comparable with previous years.
Males are more than twice as likely to use drugs; although the gender difference is less
marked amongst those in their teens. Drug use is greatest amongst the white
population, irrespective of age. 
Cannabis is the most commonly used drug amongst all age groups across the UK and
prevalence is increasing; last year use in England and Wales was approximately 11 per
cent, six per cent in Scotland and in Northern Ireland, five per cent. Prevalence of all
other drugs is considerably lower; no more than two per cent for last year use. There
has been an increase in the use of cocaine and crack (accounting for increased use of
Class A drugs). There has been a decrease in the use of amphetamines and LSD.
Prevalence is particularly high in certain groups, such as young offenders, children in
need, care leavers, homeless young people (Lloyd 1998; Gilvarry 2001; DrugScope and
DPAS 2002), and children of drug-using parents (ACMD 2003). Not only are they more
likely to use, but they are more likely to use a wider range of drugs, and to use them
more often.
2.2 Drug use in the general population
The BCS for 2003/04 sampled over 37,000 adults (24,422 completed the drugs
component) aged 16 to 59 years living in households in England and Wales. Results
from this survey are not yet in the public domain and therefore cannot be included in this
report. Similarly, in Scotland, information from the SCS 2003, which had a sample size
of approximately 5,000 have not yet been fully analysed. No new information is
therefore available for these countries.
New information on prevalence is available for Northern Ireland through the 2002/03
Drug Prevalence Survey (NACD and DAIRU 2003), which sampled over 3,500 15 to 64
year olds. Lifetime prevalence of any drug was 20 per cent (Table 3), the lowest in the
UK22, reflecting the fact that use of illicit drugs has always been less prevalent in
Northern Ireland. However, as elsewhere in the UK, use among younger adults is higher
and growing: 29 per cent of those aged 15 to 24 years reported lifetime prevalence.
Similar prevalence rates can be seen among those aged 15 to 34 years in Table 3.
Prevalence amongst males was shown to be higher than amongst females (Table 4).
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22 When compared to earlier data from England, Scotland and Wales.
Table 3: Prevalence of illegal drug use in Northern Ireland by age (%): 2002/03
Source: National Advisory Committee on Drugs and Drug and Alcohol Information
Research Unit 2003.
Table 4: Prevalence of illegal drug use in Northern Ireland by gender (%): 2002/03
Source: National Advisory Committee on Drugs and Drug and Alcohol Information
Research Unit 2003.
In Northern Ireland, 17 per cent of respondents reported ever having used cannabis, five
per cent in the last year and three per cent reported recent use.
2.3 Drug use in the school and youth population
Amongst school age children, the latest available information for England (headline
figures only; NatCen/NFER 2004), and Northern Ireland (DHSSPNI 2004a) is for 2003;
Scottish data are from SALSUS 2002 (CAHRU 2003), and information from Wales on
cannabis use for 2002 (Clements et al. 2004). The English survey has a sample size of
approximately 10,000 pupils aged 11 to 15 years. In Northern Ireland, over 7,000
individuals aged 12 to 16 years were sampled, and in Scotland, there were
approximately 23,000 13 to 15 year olds (see Table 5). 
In 2003, headline figures for England (NatCen/NFER 2004) suggest that drug use
amongst young people has begun to stabilise:
• 21 per cent had taken drugs in the last year (20% in 2001 and 2002);
• 12 per cent had taken drugs in the last month (as in 2002 and 2001); and 
• eight per cent of 11 year olds and 38 per cent of 15 year olds had taken drugs in 
the last year (6% and 36% respectively in 2001, UK Focal Point 2003). 
Figures for Scotland are from SALSUS 2002 and were reported by UK Focal Point
(2003). There have been no changes since 1998 in the proportion of 13 year olds
Prevalence Age (years)
15-24 15-34 15-64
Male Female Male Female Male Female
Lifetime 36.0 22.1 38.5 23.6 27.0 13.9
Last year 20.6 7.7 16.6 6.1 9.5 3.1
Last month 14.3 3.4 9.9 2.4 5.7 1.1
Prevalence Age (years)
15-24 15-34 15-64
Lifetime 29.1 31.1 20.4
Last year 14.2 11.3 6.2
Last month 8.9 6.1 3.3
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23 The corresponding figure for this cell has not yet been published, and as such the 2002 figure has been used instead
(so that an idea can be given of the situation).
24 The surveys cited here have different bases in terms of the age range included, the timing of the survey within the
calendar year, and the methodology.
25 Northern Ireland data are for 15 to 16 year olds. 
26 The corresponding figure for this cell has not yet been published, and as such the 2002 figure has been used instead
(so that an idea can be given of the situation).
reporting having taken drugs, and amongst 15 year olds, while there was an increase,
this was not significant. 
There are methodological issues24 around using data from different surveys to make
comparisons between the administrations within the UK; problems are exacerbated by
the fact that surveys were not completed in the same time period. Nevertheless, given
this caveat, Tables 5 and 6 show the differences between England, Scotland and
Northern Ireland amongst young people. The only available data for Wales is for 15 year
olds from the HBCS for 2001/02, which suggest that 26 per cent of boys and 24 per cent
of girls had used cannabis in the last year (Clements et al. 2004).
Table 5: Prevalence of illegal drug use amongst the school age population in the United
Kingdom
Source: Child and Adolescent Health Research Unit 2003; National Centre for Social
Research/National Foundation for Educational Research 2003; Department of Health,
Social Services and Public Safety Northern Ireland 2004a; National Centre for Social
Research/National Foundation for Educational Research 2004.
Table 6: Prevalence of illegal drug use amongst 15 year olds in the United Kingdom
Source: Child and Adolescent Health Research Unit 2003; National Centre for Social
Research/National Foundation for Educational Research 2003; Department of Health,
Social Services and Public Safety Northern Ireland 2004a; National Centre for Social
Research/National Foundation for Educational Research 2004.
Drug use is more prevalent in the older age groups than in the younger age groups, and
more prevalent amongst males than females.
Prevalence (%) England Northern Scotland
Ireland25
Last year prevalence 38 22 33
Last month prevalence 2326 10 23 
Prevalence (%) England Northern Scotland
Ireland
Lifetime prevalence 2723 22 24
Last year prevalence 21 14 22
Last month prevalence 12 7 14
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Cannabis, as in the adult population, is the most commonly reported drug in school
surveys: in England, 13 per cent of 11 to 15 year olds had taken cannabis in the last
year; 21 per cent in Scotland; and 14 per cent in Northern Ireland for 12 to 16 year olds.
In Northern Ireland’s previous survey (2000, see UK Focal Point 2003), volatile
substances were reported as the most commonly used drug by 12 to 16 year olds (15%
reported lifetime prevalence) and lifetime prevalence of cannabis was 12 per cent. In
comparison, the latest survey results for Northern Ireland suggest ten per cent for
volatile substances and 17 per cent for cannabis. However, the most recent available
data show that the situation is different for younger pupils. In England, amongst 11 year
olds, use of volatile substances was more common than cannabis in the last year (6%
and 1% respectively) (NatCen/NFER 2004). The picture is the same in Northern Ireland
with 1.8 per cent of 12 year olds reporting cannabis use in the last year compared to 3.9
per cent reporting solvent use (DHSSPNI 2004a).
2.4 Drug use among specific groups
Research into substance use among specific groups, who tend not to be included in
general population surveys, has been undertaken as part of the Vulnerable Groups
Research Programme funded by the Home Office. The aim was to investigate patterns
of drug use and access to services through researching: people leaving care; homeless
young people; young people in contact with youth offending teams; young drug users
who are in contact with drug services; and young people involved in sex work. 
2.4.1 Care leavers 
Research was conducted with 200 young people (with an average age of 18 years) in
the process of leaving or having recently left care and with young people who had left
home at a young age (‘runaways’) (Ward et al. 2003). There were high levels of self-
reported drug use compared with general population surveys: 
• almost three-quarters (73%) have used cannabis during their lifetime, a third 
(34%) on a daily basis;
• 10 per cent had used cocaine within the last month; 
• 15 per cent had used ecstasy within the last month; 
• lifetime prevalence of heroin and crack cocaine was around 10 per cent. 
Of note is that steadily lower levels of consumption were reported as young people
assumed or approached independent living status. The research suggested that
practical responsibilities (such as household management) when well planned as part
of the care-leaving transition, encourage more responsible levels of drug consumption.
2.4.2 Young offenders 
Research into drug use amongst 293 Youth Offending Team (YOT) clients aged 14 to
18 years shows prevalence of any illegal drug to be extremely high (Hammersley et al.
2003). Eighteen per cent had used crack cocaine and 11 per cent, heroin; but use of
these drugs was infrequent. It was suggested that drug use and offending in this cohort
may represent a period of intense misbehaviour, which may or may not be temporary.
There was no evidence that age of first use of drugs has dropped (although progression
to more serious substances has speeded up) or that heroin and cocaine dependence
have become commonplace (few reported dependence although 15% were rated by the
Assessment of Substance Misuse in Adolescents (ASMA; see Willner 2000) as at high
risk of substance abuse problems). Forty per cent or more of the cohort felt there was
some relationship between their substance use and their offending. 
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2.4.3 Homeless young people
A study into substance use amongst 160 homeless young people aged 25 years and
under in England and Wales found 95 per cent of them had used drugs (typically
beginning experimentation aged 14 years). Cannabis, amphetamines and ecstasy use
were particularly high: used in the last month by 68 per cent, 12 per cent and 21 per cent
respectively. A substantial minority had used heroin (21%) and crack cocaine (18%) in
the last month. There was evidence of unsafe injecting practices and 23 per cent had
accidentally overdosed on drugs or alcohol (Wincup et al. 2003). 
2.4.4 Sex workers 
Research has also been conducted amongst participants with experience of both sex
work and drug use. Cusick et al. (2003) surveyed and interviewed 125 participants, with
an age range of 16 to 64 years and a mean age of 26.7 years. They found that the
experiences of sex work and drug use may be mutually reinforcing, and that the
relationship between the two is potentially strengthened when individuals are exposed
to the following ‘trapping factors’:
• involvement in prostitution and/or ‘hard drug’ use before the age of 18 years;
• sex working ‘outdoors’ or as an ‘independent drifter’; and
• experience of at least one additional vulnerability indicator such as being ‘looked 
after’ in local authority care or being homeless.
The most vulnerable and most damaged participants were exposed to all three ‘trapping
factors’. They also shared the following characteristics:
• they were young. The mean age of first prostitution was 13.8 years;
• they were likely to have been ‘looked after’ (78% of this group); and
• they had supported at least one ‘boyfriend’s’ problem drug use.
2.5 Attitudes to drugs and drug users
There is no new information available for 2003. Please see Chapter 1.5.1 of this report
for details of young people’s attitudes to cannabis and Chapter 1.4 (UK Focal Point
2003) for further details regarding attitudes and debates.
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3. Prevention
3.1 Overview
Within current UK Drug Strategy there are three main strands of prevention activities:
• preventing young people from using drugs;
• preventing young people, particularly the vulnerable, from becoming problem 
drug users; and 
• preventing the use of Class A drugs (UKADCU 1998; Northern Ireland Office 1999; 
Scottish Office 1999; National Assembly for Wales 2000; Drugs Strategy 
Directorate 2002a).
Drug education is a key component of prevention. In England and Northern Ireland, it is
a statutory part of the national curriculum. The aim is to develop pupils’ knowledge,
skills, attitudes and understanding about drugs in order to resist them. In Scotland, while
there is no statutory curriculum, the majority of schools provide drug education (Scottish
Executive 2003a). The Welsh Assembly is developing guidance. 
Information campaigns focused particularly on the young and their parents are also part
of the prevention strategy27.
Vulnerable young people and those living in high crime areas are known to be at risk of
using drugs and of making the transition into problem use, and there is concern that the
vulnerable may not be reached in the school setting. Drug prevention in areas of social
disadvantage is seen as part of a wider need to address social deprivation (Drugs
Strategy Directorate 2002a). The Positive Futures programme uses sport and arts to
engage the most vulnerable young people and encourage them to develop the skills to
help them resist drugs and, if required, re-enter education and training (Drugs Strategy
Directorate 2003a). In areas of social disadvantage, Health Action Zones have initiated
drug prevention projects working with vulnerable young people (DH 2002a).
3.1.1 Drug prevention in community and outreach settings
In England, Wales and Northern Ireland, the Communities Against Drugs (CAD)
programme28 supports action at a local level (Home Office 2004a). In addition, the
Scottish Drugs Forum (SDF)29 works to develop the capacity of communities whilst
Scotland Against Drugs (SAD)30 provides support to initiatives aimed at drug prevention
in local communities. 
There are a number of local initiatives aimed at prevention in recreational settings
including peer education (Shiner 2000), outreach and information campaigns
(Henderson 2002). Particular concern is with drugs and driving (Scottish Executive
2000; Tunbridge et al. 2001).
3.2 Universal prevention
In 2004, the Health Development Agency (HDA) published a review of reviews of drug
use prevention initiatives (Canning et al. 2004). This considered evidence from selected
27 See http://www.talktofrank.com and http://www.knowthescore.info for more details.
28 In England and Wales, CAD has now been subsumed under the Building Safer Communities programme (BSC).
29 For more information, please see http://www.sdf.org.uk. 
30 For more information, please see http://www.sad.org.uk.
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systematic reviews, other reviews and meta-analyses published since 1996 with the aim
of identifying interventions shown to be effective in preventing or reducing drug use. The
review concluded the following: 
• the impact of prevention programmes has not been adequately reviewed;
• school-based interventions can delay for a short time the onset of drug use by non-
users, and temporarily reduce use by some current users; although the effects 
decrease with time;
• universal prevention programmes are most effective for lower-risk adolescents;
• effective programmes include those that modify attitudes, normative beliefs and/or 
impact on behaviour such as preventing or reducing drug use. They require 
booster sessions; intensity does not equate to effectiveness;
• neither Life Skill Training (LST) nor other prevention programmes have had a 
major impact on drug use and drug problems; although LST has had a positive 
impact on use;
• interactive education programmes using peers are more effective than non-
interactive programmes; although peer leaders benefit most;
• parent-orientated programmes are poorly attended and not adequately evaluated;
• information-based programmes such as DARE (Drug Abuse Resistance 
Education)31 have had little impact;
• teacher-led programmes require more research evidence; and
• most British programmes are not properly evaluated in terms of outcome.
The National Collaborating Centre for Drug Prevention (NCCDP) was established by the
HDA and the Centre for Public Health, Liverpool John Moores University in 200432.
Initially it will focus on seven to 25 year olds, and will be examining evidence at all levels
from local to international. The Centre will update the work of Canning et al. (2003), as
well as produce an Effective Action Briefing and an Evidence Review of the grey
literature of drug prevention in young people, and associated topics, including a health
economic evaluation.
In England, FRANK33 was launched in 2003, jointly funded by the Home Office and
Department of Health, and supported by the Department for Education and Skills. It
aims to prevent 11 to 21 year olds from becoming problem drug users, discouraging
involvement with Class A drugs, and encouraging both parents and young people to
become better informed. The campaign delivers its messages using a 24-hour helpline,
television, radio, press and specifically targeted information and stickers. Its promotion
has involved supporting stakeholders to deliver the message locally. Preliminary
findings are that 84 per cent of young people and 70 per cent of parents are aware of
FRANK. Each element of the campaign has been researched and tested to ensure that
all the public information is acceptable to the target audiences. By June 2004, the
campaign had had over 1.5 million visits to its website and received over 425,000 calls
to the helpline. Research among 15 to 18 year olds and parents of 11 to 17 year olds
showed that FRANK was welcoming, helpful, and non-judgmental for those with a
problem; and there was strong recognition of the campaign among teenagers. Users of
the FRANK service reported:
• those who sell hard drugs should be punished (85%);
• those with a drug problem should be offered treatment (86%) (LVQ Research 2004).
31 For more information, please see www.dare.uk.com. 
32 For more information, please go to http://www.cph.org.uk/nccdp. 
33 More information on this national public information campaign can be found at: http://www.talktofrank.com.
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In Scotland, the Know the Score communications strategy34 provided information about
the risks of drug use to young people, adults (who may be parents) and professionals.
In 2003, their campaigns concentrated on providing advice about drug-assisted sexual
assault, volatile substance abuse and cannabis reclassification. The Health Promotion
Agency runs similar campaigns in Northern Ireland (Health Promotion Agency 2003a). 
3.2.1 Schools
In 2004 in England, the Department for Education and Skills issued guidance on drugs
(DfES 2004). This sets out the school’s role in relation to all drug matters, providing
guidance on both the content and organisation of drug education, and the management
of drugs within school boundaries. The document defines drugs as including alcohol,
tobacco and illegal drugs, as well as medicines and volatile substances, as these are of
particular significance to pupils. It states that:
• schools should have a drug education programme which is developmental and 
appropriate to the age, maturity and ability of pupils. It should cover, as a minimum, 
the statutory elements included in the National Curriculum Science Order for each 
Key Stage; 
• drug education should be delivered as part of Personal, Social and Health 
Education (PSHE) and citizenship;
• the programme should be based on pupils’ views, building on their existing 
knowledge and understanding; and
• drug education should be taught by skilled and confident teachers.
In addition:
• schools should develop a range of procedures for managing drug incidents, 
understood by all members of the school and documented within the school drug 
policy;
• schools should make clear that the possession, use or supply of illegal and other
unauthorised drugs within school boundaries is unacceptable; and
• schools and police should establish an agreed policy which clarifies roles and 
mutual expectations.
Within these guidelines, the DfES has also addressed which issues need to be
considered before implementing drug testing. These include gaining appropriate
consent from parents (and pupils where they are deemed competent), whether testing
is consistent with their pastoral responsibility, whether there is appropriate support and
whether it is an effective use of resources. Where schools decide to test their pupils, it
must be accounted for in the school’s drug policy. 
Schools are also expected to ensure that pupils vulnerable to drugs are identified and
receive appropriate support either from within the school or through referral to other
services, with clear referral protocols. All staff are expected to receive drug awareness
training, understand the school’s drug policy and their role in its implementation.
In Northern Ireland, new guidance was issued in 2004 (DENI 2004). This states that
schools have a duty in law to:
• teach drug education, as part of the Health Education cross-curricular theme;
• have a drug education policy, and publicise it in their prospectus;
• inform the police if they suspect a pupil to be in possession of a controlled drug;
• have their drug education monitored for effectiveness by the Education and 
Training Inspectorate; and
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34 For more details on their campaign, please see http://www.knowthescore.info. 
35 See http://www.sad.org.uk.
36 For more information, please see http://www.wales.gov.uk/subicsu/content/substance/sub-misuse-team-e.htm. 
37 For more information see http://www.drugs.gov.uk/WorkPages/YoungPeople/Blueprint/EvidenceBase. 
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• train teachers as a priority to enable them to deliver drug education programmes 
effectively and to deal with drug-related issues as they arise.
In Scotland, while there is no statutory curriculum, 99 per cent of schools (out of nearly
3,000 publicly funded schools) provide drug education (Scottish Executive 2003a).
Guidance is available to assist with content, and advise teachers (Scottish Executive
2003b). Scotland Against Drugs (SAD) aims to: provide teachers with the necessary
training and resources; make young people aware of the latest information on drugs;
and empower them to make informed choices. SAD also supplies a range of drug
education materials35.
In 2003, Scottish schools were also provided with a self-evaluation tool within the series,
How Good is our School, to help assessment of programmes (HM Inspectorate of
Education 2002). Her Majesty’s Inspectorate of Education is to undertake a focused
inspection of drug education in schools. 
Guidance for schools is currently being developed in Wales, through an All Wales
Schools Programme36. 
Schools in the North West of England and the East Midlands began to pilot the Blueprint
Drug Education Programme amongst 11 to 13 year olds during 2003 (Home Office
2003; see UK Focal Point 2003). This programme seeks to determine how international
research on effective drug prevention can be adapted within the English system, and is
based upon evidence that suggests that combining school-based education on drugs
with parental involvement, media campaigns, local health initiatives and community
partnerships is more effective than school interventions alone. Six million pounds (€8.5
million) has been allocated to this programme, which will be assessed over two years37.
3.2.2 Families
Following work by the Scottish Executive’s Effective Interventions Unit (EIU) to review
the impact of drug use on families and carers, and the role of family support groups,
2003 saw the establishment of the Scottish Network of Families Affected by Drugs,
using funding from recovered criminal assets. The Network aims to address the needs
of this population (EIU 2004a).
3.2.3 Communities
Engaging communities in drug prevention remains a priority of UK drug policy (see
Chapter 3.1).
3.3 Selective/indicated prevention
3.3.1 Recreational settings
A survey of 760 club-goers alongside 26 in-depth interviews in the South East of
England confirmed that drug prevalence is far higher among this group than among
other young people; lifetime prevalence was 79 per cent (as opposed to 50%). They
used a wide range of drugs, increasingly synthetic drugs such as ketamine (35%) and
GHB (13%). Clubbers were aware of health and legal risks; they had adopted strategies
to minimise risks such as avoiding unknown dealers (Deehan and Saville 2003).
In Scotland, Crew 2000 has organised a coalition of young people, club goers and
others to produce information about how to reduce the risks involved in drug use38.
The Health Promotion Agency for Northern Ireland launched a range of posters for pubs
and nightclubs targeting 18 to 30 year olds about the dangers of drugs (Health
Promotion Agency 2003a).
3.3.2 At-risk groups 
In England, guidance was published in 2003 for professionals working in the statutory
or voluntary sectors who provide a service to children and young people, most of whom
are vulnerable (Britton and Noo 2003). The guidance discusses their responsibilities for
identifying the young people’s substance-related needs, and provides a framework for
doing so within existing procedures.
Research into key elements of the Positive Futures projects suggested that there
appear to be many factors39 that help projects work effectively (MORI 2003) (see
Chapter 9.2.2). An impact study is due to report in 2004. 
In Scotland, the Partnership Drugs Initiative (PDI) issued grants to support voluntary
sector work targeted at: families where parents use drugs; pre-teen children at high risk
of developing patterns of problem substance use; and young problem drug users. By the
end of 2003, 52 projects were funded. An evaluation of 17 has been completed (EIU
2004b). Findings suggest that many of the projects are making a significant input with a
range of factors contributing to their success: careful planning of projects that are well
integrated with their host agency or agencies; clarity of purpose; having a flexible,
holistic client-centred approach; a clear model of care and support with well-defined
boundaries; in-house expertise; and training. One area which many of the projects
needed to address was how to define criteria for the closure of cases.
The second stage in the national evaluation of the pump-priming drug prevention
initiative reported in January 2004. Seven million pounds (€10 million) was distributed
to Health Action Zones (HAZs) in deprived areas of England in order to develop services
targeted at vulnerable young people (Bauld et al. 2003). The report concluded that
although the initiative did facilitate the development of interventions, it was felt that the
services were too small, too localised, and in some cases, too short-term to do so
effectively. Subsequently, this raises questions about the merits of distributing relatively
limited amounts of very short-term funding.
3.3.3 At-risk families
In Scotland, services for children and families suffering from the effects of drug use are
being improved through the Changing Children’s Services Fund40.
38 See www.crew2000.co.uk for further details.
39 Including flexibility, good relationships with partners and referral agencies, sessional staff, and the community itself.
40 See http://www.childreninscotland.org.uk/html/poly_c_cr.htm.
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4. Problem drug use
4.1 Overview
Population-based surveys, because of the often hidden nature of problem drug use, are
considered to be of limited use in estimating its full extent. Instead, national prevalence
estimates can be derived from a range of methods, with the multivariate indicator
method being the favoured approach. This combines local prevalence estimates along
with routinely available indicator data. Table 7 shows the national prevalence rates for
the UK, although Wales has not been included as their last national prevalence rate was
derived in 1994 and so is now thought to be obsolete. 
Table 7: National prevalence estimates for problem drug use in the United Kingdom
Source: Information Statistics Division, Scotland 200241; McElrath 200242; Frischer et
al. 200443.
Local estimates are usually derived from specific research studies that employ slightly
different definitions of what constitutes problem drug use. In this instance, it is the
capture-recapture method that is the most widely used. At present, these are only
available for Scotland and parts of England. Local prevalence estimates of problem drug
use in Scotland range from 2.9 in the Orkney Isles to 30.8 per thousand (confidence
interval (CI) = 26.6-36.7) in Glasgow (ISD 2002). In Greater Manchester, estimates of
local prevalence of problem drug use are 13.9 per thousand of the population aged 16
to 54 years old (19,255, 95% CI of 18,731-21,853; Millar et al. 2004).
Information on clients presenting to treatment is collected from the Drug Misuse
Databases44 (DMDs) in each administration, which gather data on all presentations from
those seeking treatment from specialist drug services (outpatients), inpatient services
and general practitioners. For those presenting for treatment in Great Britain, the main
Problem drug use              Injecting use
Administration Year
Number Rate per Number Rate per 
thousand thousand 
population population
8.91 2.89
England 2000/01 287,670 95% CI= 93,185 95% CI=
8.53 to 9.29 2.87 to 2.91
0.76
Northern Ireland 2000 828 95% CI= No No
0.63-0.93 estimate estimate
16.65 7.737
Scotland 2000 55,800 95% CI= 24,696 95% CI= 
16.45 to 17.53 5.87 to 8.58
41 ISD (2002) derived their national estimate through using the sum of the 32 local prevalence estimates. Here,
problem drug use is defined as opiate and/or benzodiazepine use.
42 McElrath (2002) used the capture-recapture method for Northern Ireland. Here, problem prevalence is defined as
heroin use.
43 Frischer et al. (2004) used information gathering to collect the data for England.
44 In England, the National Drug Treatment Monitoring System (NDTMS) replaced the DMD in April 2001.
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drug is heroin (varying between 49% and 67% of treatment presentations). In Scotland,
diazepam continues to be the second most commonly used drug after heroin.
Elsewhere in the UK, diazepam use is less common. In Northern Ireland, just over a
third of those presenting for treatment use opiates and nearly half use cannabis as their
main drug. Lifetime prevalence of injecting varies between 27 and 59 per cent. For all
presentations, a third are under 24 years of age and a quarter are aged between 25 and
29 years; approximately three quarters are male. 
4.2 Prevalence and incidence estimates
4.2.1 National prevalence
Using the available estimates of national prevalence for England, Northern Ireland and
Scotland, an estimate of national prevalence for the UK as a whole has been calculated.
This assumes that the prevalence rate for England (8.91 per thousand) applies to
Wales. The estimate for problematic drug users is 9.35 per thousand (360,811 with a CI
of 8.99 to 9.79 per thousand). For injecting drug use, the estimate is 3.2 per thousand
(123,498 with a CI of 3.07 to 3.34 per thousand population aged 15 to 64 years).
More recent estimates of problem drug use and drug injecting prevalence for 2003 have
just been derived for the whole of Scotland; these estimates are not due to be in the
public domain until late 2004.
4.2.2 Local estimates
Local prevalence estimates45 are available for 14 areas covering 24 of the 149 Drug
(and Alcohol) Action Teams (D(A)ATs) in England (published in 2004). Estimates for
prevalence of problem drug use varied from 0.2 per cent to 1.5 per cent of the resident
population. Estimates for injecting drug use varied from nought to one per cent (Frischer
et al. 2004).
Studies in Brighton, Liverpool and London considered the age range 15 to 44 years. The
prevalence of problem opiate use was estimated to be 11.0 per thousand of the total
population in 12 London boroughs (N=2,623,362; CI= 8.53-16.40). The prevalence of
injecting drug use was estimated to be 6.4 per thousand in the London boroughs
(N=2,623,362; CI=5.26-8.24), 9.3 per thousand in Brighton (N=2,304; CI=6.11-15.08),
and 6.6 per thousand in Liverpool (N=439,476, CI= 5.79-11.31) (Hickman et al. 2004).
45 Derived from capture-recapture studies in 2000/01.
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4.3 Profile of clients in treatment
Table 8 shows the latest available data on new presentations to treatment for the UK.
Table 8: New presentations for treatment in the UK
Source: National Drugs Evidence Centre; Information and Statistics Division, Scotland;
Department for Health Social Services and Public Safety Northern Ireland; Department
of Health.
4.3.1 Substances used
Opiates continue to be the most common main drug at approximately 67 per cent of
those newly presenting for treatment, cannabis accounts for nine per cent, crack, five
per cent, cocaine, four per cent and benzodiazepines are at two per cent. Males
represent 72 per cent of presentations. Approximately 27 per cent of those presenting
for treatment have ever injected, and 21 per cent currently inject. In Northern Ireland,
nearly half (47%) of new treatments concern cannabis as the main drug involved. This
is far higher than elsewhere in the UK. In addition, the Northern Ireland percentage of
new presentations reporting injecting is much lower at 9.3 per cent, although amongst
opiate users, 53 per cent inject (DHSSPSNI 2004b). 
For the UK as a whole, it is difficult to describe trends as the relevant information for
England, by far the largest of the countries, is for 2000/01. However, figures for Scotland
are available and despite concerns about lack of treatment for stimulant users, and
therefore, a lack of incentive to present to treatment services, the percentage of
individuals reporting use of cocaine increased from two per cent in 1998/99 to seven per
cent in 2002/03. The use of crack has increased from one to three per cent. The
proportion of new clients reporting the use of diazepam in Scotland has remained
broadly similar over the past five years (reported by 37% of those making presentations,
although not necessarily as their main drug of use); ecstasy use has also remained
reasonably constant at around five per cent over recent years (ISD 2004). These data
also indicate an increase in injecting as 42 per cent reported that they had injected in
the past month. This is an increase from the relative stability of previous years (in
1998/99, 39%; in 2001/02, 38%). The rise in new individuals reporting injecting in the
last month was reflected in all age groups but particularly so in the 20 to 24 age group.
However, there was a fall from previous years in the number of current injectors
reporting that they had shared needles or syringes in the previous month (32% of
current injectors; 34% in 1998/99; 36% in 2001/02). 
Administration Year
Number of new 
presentations 
England46 2003/04 81,547
Northern Ireland47 2002/03 1,368
Scotland48 2002/03 11,433
Wales49 2000/01 3,730
TOTAL 98,078
46 These data are from NDTMS returns for 2003/04 as supplied by NDTMS 1st September 2004. The Drug Misuse
Research Unit compiled these data for UK Focal Point.
47 Data for 2002/03 were provided by the NIDMD.
48 Data for 2002/03 were provided by the ISD.
49 These data were extracted from the DMD by the Department of Health.
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4.3.2 Centre types
See Chapter 5.3.
4.3.3 Other specific sub-populations
Preteen drug use
Research in Glasgow and Newcastle suggests that among the 2,000 participants aged
10 to 12 years, four per cent had used drugs (McKeganey et al. 2003). Whilst principally
confined to cannabis, a very small number had used heroin. Early age of onset was
often combined with a wide range of problem behaviours, deprivation, and/or with
having a family member who used drugs. 
4.4 Main characteristics and patterns of use from non-treatment sources
There is no new information available for 2003. Please see UK Focal Point (2003) for
details of after-care and reintegration in Chapter 11.3.
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5. Drug-related treatment
5.1 Overview
UK drug strategies identify treatment as being effective in tackling drug use and,
therefore, indicate a need to increase its availability and quality (Northern Ireland Office
1999; Scottish Office 1999; National Assembly for Wales 2000; Drugs Strategy
Directorate 2002a). As such:
• in 2000, the Effective Intervention Unit (EIU) was established to identify and 
disseminate effective practice in Scotland. 
• in 2001, the National Treatment Agency for Substance Misuse (NTA) was 
established in England to: increase the availability, capacity and effectiveness of 
drug treatment; develop a range of quality standards and guidelines; double the 
number in treatment over 10 years from a baseline of 100,000 in 1998; and to 
increase the proportion who successfully complete or, if appropriate, continue 
treatment. 
• the Department of Health, Social Services and Public Safety (DHSSPSNI) in 
Northern Ireland, and the Welsh Assembly are responsible for similar 
arrangements.
Treatment for those in the criminal justice system is also emphasised, and is a key
component of UK Drug Strategy (see Chapters 9 and 12).
The Updated Drug Strategy clarified that while treatment services should continue to
seek abstinence, reducing the harms associated with problem drug use is a key
objective (Drugs Strategy Directorate 2002a). Treatment providers are to offer
prescribed treatment, advice and information, needle exchange, care planned
counselling, structured day care programmes, community prescribing, inpatient drug
treatment and residential rehabilitation. In addition, drug users are to be offered relapse
prevention and aftercare programmes, hepatitis B vaccinations, and testing and
counselling for hepatitis B, C, and HIV (DH 2002b). With regards to prescribed
treatment, oral methadone maintenance is common in treating heroin addiction,
although recently buprenorphine has been introduced as an alternative (see Chapter
11). Specialist treatment for crack users is being developed as part of the National Crack
Plan (Drugs Strategy Directorate 2002b). Such services are provided by specialist
agencies in the statutory and voluntary sector, and increasingly by general practitioners.
Young people do not benefit from treatment services directed at adults. They require
separate services which address their specific needs as their drug use is not entrenched
and may often reflect other personal and social problems, which are best met by
mainstream children and adolescent services (Drugs Strategy Directorate 2002a).
Referral into treatment through the criminal justice system and whilst in prison, is a
component of UK Drug Strategy (see Chapters 9 and 12).
There has been considerable investment in research into treatment over the last few
years. The Department of Health has provided £1.4 million (€2 million) over three to four
years for research through the Drug Misuse Research Initiative (see Chapter 7.2). 
5.2 Treatment systems
The Scottish Executive has recently undertaken a review of drug treatment and
rehabilitation services (Scottish Executive 2003c), but the report is not yet published. A
review of Welsh Substance Misuse Services in 2002/03 has also been undertaken
(National Assembly for Wales 2003). It found many of the problems encountered within
treatment services elsewhere in the UK prior to the development of improvement
strategies: a complex service structure, a plethora of planning structures,
commissioners and funding streams, too many short term initiatives, and under
resourcing. A number of initiatives are currently underway to rectify these problems.
Community Safety Partnerships replaced D(A)ATs in Wales in taking responsibility for
improving drug treatment, and are developing Substance Misuse Action Plans locally50.
Substance Misuse Regional Teams provide advice at the local level and a Substance
Misuse Treatment Framework is currently being developed.
Expenditure available for treatment in the UK has risen to £503 million (€714 million) in
2003/04 (see Chapter 1.4.1). By 2004/05, this will be £573 million (€814 million) (Drugs
Strategy Directorate 2002a).
5.2.1 Treatment presentations
Recent figures show that the number of people receiving treatment for their drug
problem in England has increased by 41 per cent since 1998, and waiting times have
been cut by two-thirds since December 2001. In 2003, 141,000 people received
treatment, suggesting that the target of doubling the number in treatment over ten years
to 200,000 in 2008 may be met (NTA 2003a). See Table 8 for further information for the
UK on the number of new treatment presentations (Chapter 4.3) (which is distinct from
numbers in treatment as quoted above).
5.2.2 Service standards
The NTA has been involved in a number of projects including the production of guidance
and standards for the commissioning and provision of drug treatment services, and
working to build capacity to ensure services are developed in England (see Chapter
7.2)51. In 2003, the agency also took over responsibility for the National Drug Treatment
Monitoring System (NDTMS), which collects and analyses information on treatment
provision.
5.2.3 Under-representation in services
The Diversity Team in the Home Office continues to address the under-representation
of certain population groups (such as women and minority ethnic groups) in services. To
tackle this issue, drug services are expected to be more flexible and willing to develop
methods for attracting and maintaining these groups into treatment. Consultation on
how to access them began in 2004. A number of pieces of research have been
undertaken in this area, and guidance has been issued for street homelessness
(Randall et al. 2002), begging (Drugs Strategy Directorate 2004a) and those involved in
street prostitution (Hester and Westmarland 2004; Hunter and May 2004). 
5.2.4 Research into treatment 
A programme co-ordinator has been appointed to help with overall co-ordination,
communication and dissemination of the Drug Misuse Research Initiative programme.
40
50 These concern both alcohol and drugs.
51 For more information, please see http://www.nta.nhs.uk. 
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A number of research projects were completed in 2003/0452. 
1. A step-by-step epidemiological needs assessment of dual diagnosis, and the
design of a training and service response model (Strathdee et al. 2002) (see
Chapter 6.4).
2. Research into the nature and extent of comorbidity in England and Wales
(Frischer et al. 2003) (see Chapter 6.4).
3. A pilot feasibility study for a multi-centre randomised controlled trial to compare the
outcomes and costs of injectable versus oral methadone (Metrebian et al. 2003).
However, the study was unable to recruit a sufficient number of opiate dependent
injecting users presenting for treatment, suggesting that the target population does
not appear to be presenting to treatment.
4. Research into preteen drug use (McKeganey et al. 2003) (see Chapter 4).
5. Research into the effect of waiting times (Donmall et al. 2003). This found that
agencies define and measure their ‘waiting times’ in a variety of ways and stresses
the importance of clear guidance. It was suggested that waiting times should not
be used on their own as a measure of quality, at least in terms of uptake and
retention, as other factors influence these outcomes. Most consistent is the highly
significant effect that the agency itself has on whether clients are taken on and
retained; some agencies are better at engaging and retaining clients.
6. An evaluation of a brief intervention model for use with young non-injecting
stimulant users (Marsden et al. 2003) concluded that such interventions are
valuable for use with this group and can be successfully delivered by trained and
well-supported workers. There was evidence that such interventions were
significantly better than a basic assessment of drug use and lifestyle in
encouraging young people to reduce risky stimulant use. However, this evidence
was not sufficient enough to say that brief motivational interventions should be
delivered in practice without further development. 
5.3 Drug free treatment
In England, a new approach to treating crack/cocaine use is being piloted, focusing on
training, new occupational standards and piloting a range of new materials and tools for
drug workers to use (NTA 2003b). The pilot, along with eight existing crack treatment
services, is to be evaluated. The NTA suggests that this will constitute the largest study
of crack/cocaine treatment ever carried out in Europe (NTA 2003c). In Scotland, the EIU
is supporting the development and evaluation of a pilot psycho-stimulant service in
Aberdeen (EIU 2004c). While services for crack users are under consideration in
Northern Ireland, to date there have been only four reports of individuals presenting to
services with crack problems (DHSSPSNI 2004b).
5.3.1 Inpatient treatments 
Available information for England (2003/04), Scotland (2002/03) and Northern Ireland
(2002/03) suggests that just over four per cent of new treatments for drug problems
involved inpatient care (4,099).
5.3.2 Outpatient treatments 
Available information for England (2003/04), Scotland (2002/03) and Northern Ireland
(2002/03) suggests that just over 91 per cent of new treatments for drug problems
involved specialised drug services (outpatients) (86,264).
A further four per cent (3,987, n= 94,350) involved general practitioners.
52 Summaries can be found on. http://www.mdx.ac.uk/www/drugsmisuse/execsummary.html. 
5.4 Medically assisted treatment
5.4.1 Withdrawal treatment
Information on this is not currently monitored.
5.4.2 Substitution treatment
Northern Ireland had not seen the same level of problem drug use as elsewhere in the
UK until the last few years (House of Commons Northern Ireland Affairs Committee
2003). As such, substitute prescribing was rare. However, prevalence is increasing (see
Chapter 4) and in 2004, guidelines for substitution treatment for opiate dependence
were introduced (DHSSPSNI 2004c).
Injectable heroin and injectable methadone, while long prescribed in the treatment of
opiate addiction, albeit rarely in the UK, are to be extended in England (NTA 2003d).
Currently, 2,500 methadone and 450 heroin users receive this treatment. It is estimated
that between five and 10 per cent of patients may benefit from this. As such, new
guidance has been developed on prescribing injectable drugs (NTA 2003d). It is not the
intention of the guidance to expand the number of drug users being prescribed heroin,
but to improve the quality of prescribing practice. There are no plans to make heroin or
injectable methadone available elsewhere in the UK.
5.4.3 Other medically assisted treatment 
Only prescribed treatments are offered with medical assistance.
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53 Laboratory and clinician report data for England and Wales, Scotland, and Northern Ireland are available from the
following websites: http://www.hpa.org.uk for England and Wales, http://www.show.scot.nhs.uk/scieh for Scotland and
http://www.cdscni.org.uk for Northern Ireland. 
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6. Health correlates and consequences
6.1 Overview
There are a number of risks to health associated with drug use, in particular use of
opiates and cocaine-based drugs. These include the potential for overdose and death,
infectious diseases, mental illness, other physical health problems and health problems
for children born to mothers who used drugs during pregnancy.
6.1.1 Drug-related deaths
There are two main types of source in the UK for information on ‘acute’ deaths: 
• three General Mortality Registers (GMRs) maintained by the General Register 
Offices for England and Wales, Scotland, and Northern Ireland; and 
• the Special Mortality Register (SMR) compiled through the National Programme 
on Substance Abuse Deaths (np-SAD) based at St George’s Hospital Medical 
School.
Since 2000, when drug-related deaths (DRDs) reached nearly 2,000, the numbers have
fallen. Males are more likely to be involved, with the male to female ratio being 4.24:1.
The average age at death is around 34 years, with males tending to be five years
younger than females. Overall, most deaths occurred in the 25 to 29 age group. Over
seventy per cent of deaths are associated with opiates (chiefly heroin/morphine and
methadone), often in combination with other drugs, including alcohol. Large numbers of
deaths also involve benzodiazepines such as temazepam and diazepam. Cocaine-
related deaths, while still low in numbers, have increased substantially over the last few
years (mentioned in 9% of cases in 2002). There has been a steady increase in the
number of deaths associated with ecstasy, with a total of 202 occurring between 1996
and 2001, although this increase did level off in 2002. 
6.1.2 Blood borne infectious diseases
Data on the prevalence of blood borne infectious diseases amongst injecting drug users
(IDUs) are provided by a number of sources: 
• the Unlinked Anonymous Prevalence Monitoring Programme (UAPMP) surveys of 
IDUs in contact with drug services in England, Wales and Northern Ireland (Hope 
et al. 2001; Unlinked Anonymous Steering Group 2002); 
• the Centre for Research on Drugs and Health Behaviour surveys of IDUs recruited 
from community settings in England (Hunter et al. 2000); and 
• the Scottish Centre for Infection and Environmental Health (SCIEH) surveys of 
IDUs attending both community and drug agency settings in Glasgow (Taylor et al.
2000). SCIEH also holds anonymous epidemiological data on all those who have 
had a named HIV antibody test in Scotland since 1989 (on the HIV Denominator 
Database). 
The main source of information on newly diagnosed HIV/AIDS infections is the voluntary
confidential case reporting of newly diagnosed infections by microbiologists and
clinicians53. For England, Wales and Northern Ireland, reports are made to the Health
Protection Agency’s Communicable Disease Surveillance Centre (CDSC) whilst new
diagnoses in Scotland are reported to SCIEH.
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HIV prevalence among IDUs in the UK has remained at less than or around one per cent
since the mid-1990s, although in London it has been higher at or near four per cent. At
the end of 2002, there were an estimated 1,400 people living with HIV infection acquired
through injecting drug use, of whom 300 were thought to be undiagnosed. 
The prevalence of hepatitis C (HCV) amongst IDUs has been much higher at around 45
per cent, and there is evidence of increased incidence (Health Protection Agency
2003a). Prevalence of antibodies for hepatitis B (anti-HBc) has declined, levelling off at
20 per cent. Outbreaks of hepatitis A and other infections among IDUs have been
increasingly reported, including methicillin resistant Staphylococcus aureus (MRSA) as
a cause of IDU-related sepsis (Health Protection Agency 2003b) and other serious
Clostridial infections acquired through contaminated drugs (Jones et al. 2002;
McGuigan et al. 2002). This has followed reported increases in injecting risk behaviour
among IDUs (Hope et al. 2002).
6.1.3 Dual diagnosis
Prevalence and attribution of dual diagnosis remain difficult to estimate. Depression,
anxiety disorders, personality and psychotic disorders are commonly reported, although
prevalence varies with setting and specific sub-populations. There is also increasing
information regarding the attribution of mental health problems to the use of cannabis
(Patton et al. 2002; Zammit et al. 2002) and ecstasy (MacInnes et al. 2001), although
this needs further investigation. 
6.1.4 Other health correlates and consequences
Other physical health problems associated with problem drug use include thrombosis,
blood clots and gangrene (ACMD 2002).
In addition, maternal drug use can have a significant impact on unborn children. There
is evidence of high rates of early pregnancy loss and placental disruptions associated
with cocaine use, and evidence is now emerging that children whose mothers used
cocaine whilst they were pregnant are at risk of haemorrhaging as they grow older (DH
et al. 1999). Maternal heroin use is associated with low birth weight babies (DH et al.
1999). There is concern about birth defects linked to ecstasy use (Ho et al. 2001).
Benzodiazepines can cause “floppy infant syndrome” and evidence suggests it may also
be linked to major malformations such as cleft palate. Babies born to mothers exposed
to long-term benzodiazepine use risk deviation in neurological development during their
first 18 months, which can result in behavioural problems, dyslexia and attention-deficit
disorder. These problems may not come to light until puberty (Bibby 2000). Cleft palate
is also associated with amphetamine use (Bibby 2000).
Withdrawal from maternal drug use can also be problematic for babies. Withdrawal from
opiates and stimulants is not predictable and withdrawal from maternal benzodiazepines
can be severe and prolonged (Bibby 2000).There may also be a link with Sudden Infant
Death Syndrome (Bibby 2000).
There is little evidence of HIV transmission to babies in the UK through maternal
infection associated with drugs, but there is a risk of hepatitis virus transmission,
particularly HCV, where the risk of transmission amongst babies whose mothers test
positive is six per cent (DH 2002c; Siney 2002). 
54 The European Monitoring Centre for Drugs and Drug Addiction’s definition of a drug-related death includes deaths
by drug psychosis, drug dependence, non-dependent drug abuse, accidental poisoning, suicide and self-inflicted
poisoning, and poisoning of undetermined intent. Only deaths due to drugs typical of abuse (opiates, cocaine,
amphetamines, cannabis and hallucinogens) are included. 
6.2 Drug-related deaths and mortality of drug users
6.2.1 Direct overdoses and (differentiated) indirect drug-related deaths
The latest information on DRDs is for 2002. The total number of deaths has continued
to fall from its peak in 2000 by 4.9 per cent to 1,824 in 2002 (Figure 2). The male to
female ratio continues to reduce: 4.24 males to 1 female (Table 9 and Figure 3). The
overall average age fell back to 34.0 years (SD 11.4) in 2002, although the average age
of death for females remains much higher than for men, ranging from over four to nine
years higher among the four administrations.
Figure 2: Number of deaths using European Monitoring Centre for Drugs and Drug
Addiction drug-related deaths standard definition54
Source: Compiled by John M. Corkery from published data from the Office for National
Statistics, the General Register Office for Scotland (2003), and from unpublished data
provided by the General Register Office for Northern Ireland, 2004.
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Table 9: Death by age, gender and administration in the United Kingdom using the
European Monitoring Centre for Drugs and Drug Addiction drug-related deaths standard
definition, 2002
Source: Compiled by John M. Corkery from published data from the Office for National
Statistics, the General Register Office for Scotland (2003), and from unpublished data
provided by the General Register Office for Northern Ireland, 2004.
Figure 3: Death by age and gender in the United Kingdom using European Monitoring
Centre for Drugs and Drug Addiction drug-related deaths standard definition, 2002
Source: Compiled by John M. Corkery from published data from the Office for National
Statistics, and General Register Office for Scotland (2003), and from unpublished data
provided by the General Register Office for Northern Ireland, 2004.
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Age England Northern Ireland        Scotland                    UK
and Wales
Males Females Males Females Males Females Males Females
<15 1 1 0 0 0 0 1 1
15-19 45 12 16 11 0 0 61 23
20-24 177 25 67 8 1 0 245 33
25-29 227 46 75 18 2 0 304 64
30-34 239 45 62 8 0 0 301 53
35-39 205 34 51 8 3 0 259 42
40-44 104 23 31 12 1 0 136 35
45-49 61 20 19 7 0 3 80 30
50-54 38 21 5 5 1 0 44 26
55-59 3 10 7 6 0 0 10 15
60-64 7 5 3 2 0 0 10 7
The number of deaths per 100,000 of the population is different between the UK
administrations. In 2002, the rate in Scotland was 8.42 compared to 2.64 in England and
Wales, and 0.71 in Northern Ireland. The UK average was 3.08. 
Differences also emerge when looking at the various definitions used for DRDs. Figure
4 demonstrates that although the three definitions displayed show similarities until 2000,
the differences between them appear to be becoming more significant (see UK Focal
Point 2003 for further details).
Figure 4: Comparison of total number of deaths using three definitions (United Kingdom)55
Source: Office of National Statistics 2004, General Register Office for Scotland 2003,
General Register Office for Northern Ireland.
6.2.2 Mortality and causes of deaths among drug users
Overall, deaths in England and Wales in 2002 were described as being due to:
• mental and behavioural disorders (54%);
• accidental poisoning (27%);
• intentional or undetermined poisoning (18%); and 
• assaults by poisoning or drug psychoses (5 cases).
Heroin/morphine continued to account for the highest number of deaths according to all
three definitions discussed (see Tables 11 and 12). Using the EMCDDA standard, the
proportion is 63 per cent. In addition, mentions of cocaine are increasing (see Tables 10
and 11). 
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55 Drug-related deaths are defined by the UK Drug Strategy as those where the underlying cause is poisoning,
drug abuse or drug dependence and where any of the substances scheduled under the Misuse of Drugs Act 1971
were involved. 
Table 10: Mentions of specific drugs on United Kingdom death certificates
Source: Office of National Statistics 2004, General Register Office for Scotland 2003,
General Register Office for Northern Ireland.
Table 11: Drugs as a proportion of drug poisoning deaths by definition56
Source: Office of National Statistics 2004, General Register Office for Scotland 2003,
General Register Office for Northern Ireland.
There were 63 deaths associated with volatile substance abuse in 2002 (the same as in
2001). The figures for 2001 and 2002 are the lowest since 1982, and can be compared
with 1990’s peak of 152 (Field-Smith et al. 2003).
Deaths of IDU AIDS victims accounted for 5.3 per cent of the total number of AIDS
deaths in England and Wales up to the end of March 2004. In Northern Ireland the figure
was 4.7 per cent, but in Scotland was 42.0 per cent. The decline in the number of deaths
of IDU AIDS victims seen in recent years has levelled off. The UK figure of 23 for 2003
(21 in 2002) is about 14 per cent of the peak level in 1995 (159). 
6.2.3 Research into drug-related deaths
A number of studies touching on DRDs in the UK were published in the last year.
Unfortunately, these did not include any cohort mortality studies. 
A study of 221 coroners’ cases, for males aged 15 to 39 years in 1995 for which
toxicology reports were available, found post mortem evidence of drugs in 90 cases,
alcohol in 102, and both in 46. Overdose verdicts were given in 74 cases. There was
evidence of significant alcohol problems in 18 cases and drug use in 74 cases. The
1999 2000               2001                2002
Drug EMCDDA UK EMCDDA UK EMCDDA UK EMCDDA UK
Heroin/morphine 56.3 52.5 61.6 59.9 65.0 60.1 62.8 58.1
Methadone 24.4 22.8 19.1 18.5 19.7 18.3 22.9 21.2
Cocaine 5.6 5.2 4.3 4.2 6.3 5.8 9.4 8.7
Ecstasy 2.0 1.8 2.5 2.4 4.1 3.8 4.1 3.8
Diazepam 14.6 13.5 11.8 11.5 15.2 14.0 18.9 17.5
Temazepam 8.0 7.4 5.9 5.8 4.5 4.1 5.2 4.8
Total number 
of deaths 1780 1912 1955 2011 1833 1983 1824 1972
Drug 2000 2001 2002
Heroin/morphine 1204 1192 1146
Methadone 373 362 418
Cocaine 85 115 171
Ecstasy 49 76 75
Diazepam 231 278 345
Temazepam 116 82 95
48
56 Definitions used are the EMCDDA drug-related death standard definition (under those columns marked ‘EMCDDA’)
and UK Drug Strategy definition (under those marked ‘UK’).
presence of drugs at post mortem was significantly related to a verdict of accidental or
undetermined death rather than suicide. Whilst coroners determined drugs to be related
to death in 90 cases, the figure would have been recorded as 60 using the Office for
National Statistics (ONS)57 definition or 40 using the EMCDDA DRD standard
(Stanistreet et al. 2004).
DRDs were significantly lower in female than in male drug users. DRDs were between
two and six times more frequent amongst those older than 34 years than those younger
than 25 years (Bird et al. 2003).
The year 2002 saw the trend of increasing numbers of ecstasy-related deaths start to
level off. In 17 per cent of cases, ecstasy was the sole drug implicated in death and in
the remainder, a number of other drugs (mostly alcohol, cocaine, amphetamines and
opiates) were found. MDMA (3,4-methylenedioxy-n-methylamphetamine) accounted for
86 per cent and MDA (methylenedioxymethamphetamine) for 13 per cent; single deaths
were associated with MDEA (methylenedioxyethylamphetamine) and PMA (para-
metoxyamphetamine). This is the largest sample of ecstasy-related deaths so far
examined (Schifano et al. 2003). 
An important development was the publication of two studies addressing
antidepressants. The first was a study of deaths involving antidepressants which were
reported to the SMR from 1998 to 2000 (468 out of 4,167 drug-related deaths in that
period; Cheeta et al. 2004). The study found that most were suicides (80%). Tricyclic
antidepressants accounted for more drug mentions than any other antidepressants (12
per million prescriptions). SSRIs (selective serotonin reuptake inhibitors) were
associated with a significantly lower risk of toxicity but 93 per cent of deaths from SSRIs
occurred in combination with other drugs, especially tricyclics (24.5%). In ‘combination’
deaths, patients were significantly more likely to have had a history of illegal drug use.
Between 1993 and 2002, a second study looked at the 4,767 deaths that occurred in
that time involving antidepressants in England and Wales (18% of all poisonings).
Research found that over the period, age-standardised mortality rates for
antidepressants decreased from about nine to seven per million of the population for
both genders. However, unlike females, rates in males rose to a peak of 12 per million
in 1997 before falling. The number of antidepressant prescription items during the study
period rose 2.5 times to 26 million prescriptions, largely due to increased use of SSRIs
and other antidepressants. Overall, death rates in England per million antidepressant
prescription items declined, with falls in the rates for dothiepin, amitriptyline and all
tricyclics. There was no change in the SSRI rate while rates for other antidepressants
rose. Despite these trends, throughout the study period, rates were highest for tricyclics
and lowest for SSRIs (Morgan et al. 2004).
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57 Drug-related deaths are defined by the ONS as described by Christopherson et al. (1998).
6.3 Drug-related infectious diseases
6.3.1 HIV/AIDS
Figure 5: HIV prevalence among injecting drug users in the UK58
Source: Communicable Disease Surveillance Centre, Health Protection Agency; Centre
for Research on Drugs and Health Behaviour, Imperial College London.
The agency figures for HIV prevalence among IDUs in London peaked in 2001 and are
now starting to decrease. In the UK, agency figures have been relatively similar over
recent years, but showed a marked increase in 2003 (see Figure 5).
6.3.2 Viral hepatitis
Prevalence of hepatitis B (HBV) remains the same as 2002 (20% of IDUs). Prevalence
of HCV among injectors increased to 41 per cent (1,081 of 2,615) in 2003, from 36 per
cent in 1998 in England and Wales (1,151 of 3,188; Hope et al. 2001). Prevalence
among recent initiates (those who began injecting in the last three years) has also
increased from eight per cent in 1998 to 17 per cent in 2003 in England, Wales and
Northern Ireland (Health Protection Agency 2004a).  
Figure 6 shows the total number of HCV reports to be increasing for all infection routes,
and for the proportion associated with injecting drug use (which account for the majority
of cases).
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58 The figure includes information for Northern Ireland from 2002.
59 England and Wales, and Scotland have different case definitions.
60 Please refer to http://www.ukhra.org/practice_development/tuberculosis.html, or
http://news.bbc.co.uk/2/hi/health/medical_notes/100618.stm. 
61 Please refer to 
http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGui
danceArticle/fs/en?CONTENT_ID=4090417&chk=DsgbSP
Figure 6: Hepatitis C laboratory reports in the United Kingdom59
Source: Communicable Disease Surveillance Centre, Health Protection Agency;
Scottish Centre for Infection and Environmental Health.
6.3.3 Sexually transmitted diseases
There is no new information available for 2003. However, the Health Protection Agency
will be publishing a report in 2004 addressing sexually transmitted diseases, and within
that will assess the situation for IDUs (Health Protection Agency 2004b). However, this
was not in print in time for this publication.
6.3.4 Tuberculosis
Individuals can be more at risk of contracting Tuberculosis if they inject drugs60.
There is no new information available for 2003. However, the Department of Health will
be releasing an action plan in 2004 to address Tuberculosis61, which was not in print in
time for this publication.
6.3.5 Other infectious morbidity
While tetanus has rarely been reported in IDUs (Rushdy et al. 2003), an outbreak
occurred in 2003 and is ongoing: 14 cases were reported between July 2003 and
January 2004 (Hahné et al. 2004). The majority of cases had generalised tetanus and
one case is known to have died. Seven out of nine cases, for whom information on the
method of injection was available, reported subcutaneous injection of heroin (‘skin
popping’). This outbreak was probably due to contamination of heroin with tetanus
spores. There were also five cases of reports of Clostridium histolyticum infection among
IDUs from December 2003 (Health Protection Agency 2003c) and 27 cases of wound
botulism from January to August in 2004 (Health Protection Agency 2004c).
6.3.6 Research 
A community survey of at least 800 IDUs is underway at four sites (Devon, Bristol,
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62 Please see www.hpa.org.uk.
63 The sample was taken from road users aged 16 or over, who had died within 12 hours of being involved in a road
traffic accident.
Greater Manchester, and Middlesborough and Teeside). This survey of blood borne
viruses and injecting risk behaviour has been designed to aid the interpretation of
routine data collected by the UAPMP’s survey of IDUs attending drug agencies, and is
a collaborative project between CDSC and Imperial College, London. 
6.4 Psychiatric comorbidity (dual diagnosis)
Research published in 2003 estimated that from 1993 to 1998, there were at least
195,000 comorbid patients and 3.5 million general practitioner (GP) consultations
involving such patients in England and Wales (Frischer et al. 2003). Eighty to 90 per
cent of patients consulting for both drug abuse and mental illness do so for the first time.
The level of comorbidity is increasing at a higher rate among younger patients, which
indicates that comorbidity may increase in future years. Approximately one-third of
psychiatric discharges involve a supplementary rather than a main diagnosis of drug
use. In these cases, the most common diagnoses were: schizophrenia, mood (affective)
disorders, and alcohol misuse.
Last year’s report (UK Focal Point 2003) provides a comprehensive account of
comorbidity.
6.5 Other drug-related health correlates and consequences
6.5.1 Maternal Drug Use 
There is little reliable information about the numbers of pregnant females who use
drugs, though in Scotland, it is reported that the number of pregnancies involving female
drug users has risen over recent years from 2.4 in 1997/98 to 4.8 per 1,000 maternities
in the general population in 2003. This is set against an underlying decrease in the total
number of maternities. Sixty-seven per cent of the babies born to women known to be
using drugs were full-term and of normal birth weight, compared to 90 per cent of all live
births (ISD 2004).
6.5.2 Somatic comorbidity (as abscesses, sepses, endocarditis, dental health etc.)
There is no new information available for 2003. Please refer to the Health Protection
Agency for details of their published reports on severe systematic sepsis, botulism and
tetanus in IDUs62.
6.5.3 Non-fatal drug emergencies
There is no new information available for 2003, please refer to UK Focal Point (2003)
Chapter 3.4 for further information.
6.5.4 Driving and other accidents
Results from a recent study show that at least one medicinal or illicit drug was detected
in 24.1 per cent of the sample of 1,184 fatal road accident casualties63 (Tunbridge et al.
2001). In an earlier study carried out between 1985 and 1987, comparable drugs were
detected in 7.4 per cent of the sample (Everest et al. 1989). Of the 1,184 fatal casualties
17.7 per cent  tested positive for a single drug and 6.3 per cent tested positive for
multiple drug presence. Thus, one quarter of the drug incidence involved multiple drug
use. This contrasts sharply with the previous survey in which only 5.3 per cent of those
who had consumed drugs had used multiple drugs. This suggests an increase in
multiple drug use.
7. Responses to health correlates and consequences
7.1 Overview
Drug-related deaths (DRDs), infectious diseases, comorbidity and other health
consequences are key policy issues within UK Drug Strategy (Drugs Strategy
Directorate 2002a). 
7.1.1 Drug-related deaths
Government plans are to reduce DRDs by 20 per cent by 2004, from a national baseline
of 1,568 deaths, set in 1999. This is to be achieved through a number of campaigns,
treatment initiatives, better surveillance and monitoring, and research (DH 2001a).
7.1.2 Drug-related infectious diseases
In the 1980s, UK drug policy was led by a public health approach aiming to contain HIV
transmission. The subsequent action is regarded as having been successful in
containing HIV amongst injecting drug users (IDUs) by harm reduction approaches such
as providing free needles and syringes, and promoting the safe disposal of used
equipment (Stimson 1995; McVeigh et al. 2003). Needle and syringe exchange is now
offered through a range of services: specialist syringe exchanges, specialist drug
services, detached outreach, mobile syringe exchanges, pharmacy-based syringe
exchanges, and Accident & Emergency services. There are no national data currently
available; however, it has been estimated that 27 million syringes were distributed from
approximately 2,000 sites in 1997, of which 25 million were distributed in England, and
a million each in Wales and Scotland (Parsons et al. 2002). Scotland has ongoing data
on the extent and level of provision64. In 2000, funding was made available to develop
a free needle and syringe exchange scheme in community pharmacies in Northern
Ireland. With input from community pharmacists and other expert advisors, and taking
account of models of best practice developed elsewhere, the Northern Ireland Needle
and Syringe Exchange Scheme (NSES) was introduced in April 2001. Initially five
pharmacies were involved in the scheme but by the end of 2003/04, there were nine.
Pharmacies were chosen based on their willingness to participate, their location, and the
assessed need for needle exchange in the locality. In 2002/03, 67,516 syringes were
issued.
Other actions to reduce infection include: information campaigns on safer sex and safer
injecting; and HIV/AIDS, hepatitis B and C (HCV) counselling, support and testing. The
Hepatitis C Strategy for England recommends, as a national standard of good practice,
that all those attending specialist drug treatment services are offered HCV testing, and
immunisation against hepatitis B (DH 2002d). Treatment for infectious diseases is
provided as part of the NHS, including the provision of anti-retroviral treatment for HIV
and treatment for HCV; both are included in national guidelines (NICE 2004). Treatment
for wound infections is available through primary care, and Accident and Emergency
departments. In some areas, wound care is also available from needle exchange
schemes and through some specialist drug services. Those in prison have access to
HIV and hepatitis testing, and vaccination against hepatitis B.
7.1.3 Psychiatric comorbidity (dual diagnosis)
In 2001, the Health Advisory Service published the standards on caring for patients with
substance use and psychiatric problems (comorbidity or dual diagnosis) for England and
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64See http://www.drugmisuse.isdscotland.org.uk. 
Wales (HAS 2001b). Models of care provides detailed guidance on the provision of
services (DH 2002b), cross-referencing the Dual diagnosis good practice guide (DH
2002e). These set out policy and good practice in the provision of mental health services
for people with severe mental health problems who are also experiencing difficulties with
any drug, including alcohol. They reaffirm dual diagnosis as ‘core business’ and a
priority for mainstream mental health services, and emphasise the need for mainstream
mental health services to work in partnership with other agencies, such as substance
use services and Drug (and Alcohol) Action Teams (D(A)ATs). Local Implementation
Teams (LITs) are charged with implementing the policy requirements described in the
guide, working in partnership with D(A)ATs.
7.1.4 Interventions related to other health correlates and consequences
Maternity services are expected to provide appropriate facilities for the needs of
pregnant drug users and their babies. 
7.2 Prevention of drug-related deaths
Using the definition of the UK Drug Strategy for DRDs, the figure of 1,952 deaths is
about 430 above the target figure for 2004 (that of 1,254). To reduce the number,
different strategies are being adopted, in England, the National Treatment Agency for
Substance Misuse (NTA)65 has developed a range of programmes including:
• new guidance and information for generic services;
• guidance for all drug treatment providers and commissioners on overdose and 
delayed death due to blood-borne viruses (NTA 2003e);
• a range of materials for drug users awaiting structured drug treatment on how to 
reduce the risk of overdose and blood-borne infections; 
• various materials, posters, credit card-sized leaflets etc. targeting under-served 
drug users such as young people leaving care, those leaving prison, drug
treatment detoxification and rehabilitation, the homeless, crack or stimulant users 
in police custody suites; and 
• funding 10 black and minority ethnic communities, which had previously
undertaken a drug needs assessment for their local groups, to produce materials 
specifically in their own language.
The Department of Health has published guidance for D(A)ATs on providing
resuscitation training for drug users66.
Funding has also been provided for work in the following areas:
• the use of naloxone to prevent overdose by the ambulance service and the 
National Patients’ Safety Agency (NPSA);
• the use of “take home” naloxone; and
• an evaluation of supervised consumption of methadone administration by 
pharmacists.
7.2.1 Prison service
With reportedly high rates of overdose amongst prisoners released from custody (ONS
and National Addiction Centre 2003), the Prison Service for England and Wales is
drafting a new clinical standard, not only to combat the risk of suicide during drug
withdrawal, but also the risk of fatal overdose upon release from prison.
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65 See http://www.nta.nhs.uk/programme/drd3.htm. 
66 See http://www.doh.gov.uk/drugs/polguide.htm. 
The Scottish Prison Service (SPS) has undertaken a number of initiatives including:
• participation in D(A)AT DRD Steering Groups;
• an analysis of prison health care records and addiction case management files of 
all prisoners who were victims of DRDs within six months of release (2002);
• a review of clinical prescribing practices in order to reduce the risk of fatal 
overdose upon release (this will report in the near future);
• a review of the National Induction Process and as such SPS has introduced a 
harm reduction awareness session for all prisoners on admission;
• with the Scottish Executive Know the Score Campaign, SPS has produced a 
range of harm reduction material for all offenders, including young offenders; and 
• a new addictions policy advocating a treatment and integrated care focus, with the
aim to reduce DRDs amongst prisoners on release.
7.2.2 Volatile substances 
In 2003, the Scottish Executive piloted an awareness campaign on the law governing
the sale of volatile substances, which is to be rolled out across Scotland. In Northern
Ireland, a review of effective interventions has been undertaken by the Health Promotion
Agency, with an information pack being distributed to retailers (Health Promotion
Agency 2003b) and parents (Health Promotion Agency 2003c). The Department of
Health is currently developing an action plan for England and Wales.
7.2.3 Safer use training
Safer drug use training has been instigated as part of NTA guidance to reduce DRDs
(see Chapter 7.2). 
7.3 Prevention and treatment of drug-related infectious diseases
7.3.1 Prevention
In 2003, funding was provided through the Scottish Executive’s Drug Misuse Research
Programme to undertake an in-depth observational study of the injecting practices of
IDUs in Glasgow focusing on practices that could potentially facilitate the transmission
of HCV (EIU 2004d). This showed there are multiple ways in which IDUs put themselves
at risk including: reusing others’ needles or syringes; preparing or drawing up drug
solute for more than one injector; and sharing cookers, filters and water. The findings
emphasise the importance of: 
• having the means to use sterile equipment for each injecting episode; 
• ensuring IDUs understand the importance of distinguishing each other’s 
equipment; and
• ensuring IDUs understand how injecting equipment can become contaminated. 
The report suggested the provision of safe injecting rooms would help address the
needs of those who have to inject outdoors. The importance of such issues in
preventing drug-related infectious diseases has meant that legislation in the UK now
allows the legal provision of injecting equipment other than needles and syringes by
health services, with the aim of reducing the sharing of this equipment (see Chapter
1.2.3). 
In addition, the Hepatitis C Action Plan for England was launched in June 2004 (DH
2004). It prioritises prevention of infection and disease progression. Actions include:
• monitoring trends in infection;
• evaluating the effectiveness of prevention measures;
• increasing awareness and reducing the number of undiagnosed infections;
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67 See http://www.hepc.nhs.uk.
• the provision of high-quality health and social care services; and 
• co-ordinating assessment and treatment. 
For drug users specifically, new action will include:
• health promotion information explaining the risks of injecting and how to avoid 
blood borne viruses to be given to all young people entering the criminal justice 
system;
• information about how to avoid infection while abroad; and 
• an audit of needle exchange schemes.
Its launch was accompanied by a professional awareness campaign with an information
pack sent out to primary care professionals. Also being launched is the NHS HCV
awareness website67. In autumn 2004, a publicity campaign will continue to raise
awareness by addressing how to avoid the risk of infection, and promoting testing and
treatment. In addition, national standards for commissioning, delivery and monitoring of
the syringe exchange services are being established (NTA 2003f).
The Scottish Executive is currently developing their action plan, due to be launched in
autumn 2004. They have already introduced a range of measures, these include:
• revising guidelines to permit a substantial increase in the number of needles and 
syringes which can be supplied to drug users;
• a range of information materials to drug services and prisons across Scotland;
• issuing HCV materials for professionals and patients; 
• establishing a national database of patients diagnosed with hepatitis to help
evaluate the effectiveness of treatment; and
• the development of a two-tiered HCV awareness campaign by the Scottish Centre 
for Infection and Environmental Health (SCIEH), aimed at the general population 
and at high risk groups, and in particular ex and current IDUs.
Research
A community-wide survey of 500 injectors is being conducted in Glasgow. The survey
aims to determine whether increasing the supply of sterile needles and syringes to IDUs
will decrease the frequency of equipment sharing. 
A study addressing injecting drug use in areas of England (Brighton, Liverpool and
London) has suggested that the coverage of needle and syringe exchange services may
be insufficient to prevent infection (Hickman et al. 2004; see Chapter 4.2.2).
7.3.2 Counselling and testing
In 2003, with £1 million (€1.4 million) Department of Health funding, the NTA
commissioned a range of services to promote the uptake of HCV testing. Proposals
were required to clearly demonstrate good project planning and the expected impact on
the target population. Projects included:
• the production and distribution of HCV related literature;
• community and outreach initiatives;
• pre-test counselling;
• blood testing; 
• post-test counselling and support; 
• work to develop and define the HCV testing care pathways; and 
• training to support delivery of this care pathway.
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A cluster trial examining whether the introduction of dried blood spot collection at drug
agencies and prisons increases the uptake of HCV testing among IDUs is being
conducted by Imperial College, London.
7.3.3 Infectious disease treatment 
The Hepatitis Action Plan for England, published in 2004, will prioritise treatment.
7.4 Interventions related to psychiatric comorbidity
Implementation of guidance on caring for people with drug-use and psychiatric problems
(see Chapter 7.1.3) is on-going. The Scottish Executive has published similar guidance
(SACDM and SACAM 2003). The Scottish Executive plans to improve education and
awareness, and is looking towards more effective planning, and delivery of care and
treatment services (Scottish Executive 2003c).
7.4.1 Research 
A multi-method needs assessment of dual diagnosis in primary care will develop a
screening and assessment tool to identify dual diagnosis. It will assess the prevalence
of dual diagnosis and related health, social and lifestyle needs across a range of
treatment services (Strathdee et al. 2003). A two-tier assessment process was
developed for the project: a brief screen to identify at-risk dual diagnosis cases (taking
7 to 10 minutes); and for clients screening positive, a comprehensive 45 to 60 minute
assessment. This will be used in routine clinical practice through an educational
outreach training model.
7.5 Interventions related to other health correlates and consequences
A maternity module is being developed within a new Children’s National Service
Framework, setting standards for pregnant drug users and making services more
flexible and accessible. The Scottish Executive published information on working with
pregnant drug users in its guidance on working with families (Scottish Executive 2003b).
7.5.1 Prevention and reduction of driving accidents related to drug use
The Home Office has developed a toolkit on drugs and driving68. Information campaigns
are to begin in England, Wales and Scotland, including a website aimed at young
people69. The Scottish Executive and the Scottish Road Safety Campaign evaluation of
a recent TV advert aimed at discouraging people from driving under the influence of
drugs found awareness of the campaign to be high (76%) and their understanding to be
good. However, the overall impact was undermined by doubts about the credibility of the
enforcement message, in particular that actors appeared to be drunk rather than on
drugs (Ormston 2003). 
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69 See http://www.drugs.gov.uk/News/1017067613. 
8. Social correlates and consequences
8.1 Overview
Evidence suggests that there is a strong relationship between drug use and certain
characteristics of social exclusion. The correlates include: street homelessness (Randall
and Britton 2002); begging (Jowett et al. 2001); selling sex on the street (Hester and
Westmarland 2004); unemployment (Klee et al. 2002); and lack of educational
achievement, truancy and school exclusion (NatCen/NFER 2003). 
The number of cases dealt with under the law for drug offences (possession and
supply70) has generally increased since 1990 (Ahmad and Mwenda 2004). Furthermore,
although drug users commit a significant amount of crime, a causal relationship cannot
be firmly established (Coid et al. 2000). However, between a half and two thirds of those
in custody are reported to be problem drug users (HM Prison Service 2004b; ISD 2004),
less so in Northern Ireland (House of Commons Northern Ireland Affairs Committee
2003).
Drug use can also give rise to dangers associated with safety in the workplace, and
productivity (Drugs Strategy Directorate 2004b). 
Latest cost estimates are based on the study by Godfrey et al. (2002) and are for 2000.
It was estimated that drugs cost UK society between £11.1 and £20 billion (€15.8 and
€28.2 billion) a year.
8.2 Social exclusion
8.2.1 Homelessness
See Chapter 2.4.3 for research concerning homeless young people and drug use and
UK Focal Point (2003) Chapter 4.1.
8.2.2 Unemployment 
There is no new information available for 2003. Please refer to UK Focal Point (2003)
Chapter 4.1.
8.2.3 School drop out 
There is no new data available for 2003, please refer to Goulden & Sondhi (2001) for
further information.
8.2.4 Financial problems
There is no new information available for 2003. Please refer to EIU (2002) for further
information.
8.2.5 Social networks 
There is no new information available for 2003. Please refer to Belcher and Shinitzky
(1998) and National Institute for Drug Abuse (NIDA 1998) for further information.
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70 Drug use per se is not an offence, though it is against prison rules.
8.3 Drug-related crime
8.3.1 Drug offences  
Latest figures for drug offences in the UK (Ahmad and Mwenda 2004) show that over
113,000 persons were found guilty, cautioned or fined for drug offences in 2002; a 10
per cent rise from the previous year (102,610). The majority (90%) were male and 40
per cent were aged under 21. It is of note that in Northern Ireland, there were 1,924
drugs offences recorded in 2002/03, a 74 per cent increase on the previous year.
Possession and supply 
Having fallen in recent years, unlawful possession offences rose by 11 per cent
between 2001 and 2002 to 102,160. This accounted for 90 per cent of drug offences in
the UK. The majority were cannabis offences (76%, 72,850), a rise of 15 per cent from
2001. However, there was a fall in the possession of heroin (7% to 8,430), ecstasy (13%
to 4,530), LSD (one third to 70) and methadone (19% to 302). Crack offences rose to
over 1,000. Cocaine offences rose by 21 per cent to 4,030. 
The numbers convicted for unlawful supply continued to fall, albeit by less than one per
cent to 4,830. Heroin accounted for the highest number of these offences (1,500) - the
same as the previous year. Cannabis accounted for 1,150 (34% of supply convictions)
- a fall of five per cent from 2001. Ecstasy offences also fell (by 4% to 520). There was
a 25 per cent rise in convictions for the supply of cocaine: up to 440.
The number charged with possession with intent to supply continued to fall (5,980);
cannabis accounted for 1,860 (31%; 38% in 2001 of possession offences).
After a fall in 2001, the number of convictions for the unlawful production of illicit
substances rose 17 per cent to 2,060. The majority of these offences were cannabis-
related - with 1,940 convictions for production.
Trafficking 
Unlawful import or export offences have continued to decline in 2002 to 1,740.
8.3.2 Other drug-related crime
Acquisitive crime
The New English and Welsh Arrestee Drug Abuse Monitoring (NEW-ADAM) programme
took place between 1999 and 2002 (see UK Focal Point 2003). A final evaluation has
now been completed after interviewing 3,064 arrestees in custody suites in England
(Holloway et al. 2004). Data from the first two years of the survey showed a strong
association between drug use and acquisitive offending: 69 per cent of arrestees tested
positive for any drug, 48 per cent for cannabis and over a third (38%) for opiates and/or
cocaine. There was a strong association between self-reported drug use, particularly
heroin and cocaine, and self-reported acquisitive offending in the year before interview.
Drug-using arrestees reported significantly higher levels of illegal income than those
who did not use drugs; those reporting use of heroin, cocaine and crack in the last 12
months reported a mean annual illegal income of more than £24,000 (€34,000), four
times greater than those who had not used illicit drugs (£5,763 or €8,200). Drug-using
repeat offenders, 18 per cent of the sample, were responsible for 70 per cent of the total
number of acquisitive offences reported. 
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The NEW-ADAM programme has been reviewed as part of a programme to improve
measures of drug-related crime. As part of these measures a new continuous Arrestee
Survey commenced in September 2003 in a representative sample of 60 custody suites
in England and Wales. This involves computer assisted self-interviewing, covering: self-
reported offending, self-reported drug use, information on sources of illegal drugs, past
experience of drug treatment and Arrest Referral, other aspects of the Drugs
Intervention Programme (DIP)71 and drug testing arrestees. The target sample size was
9,000 arrestees.
In addition, a number of other information tools are being developed, for example, the
Offenders Index (a register of all people convicted of a ‘standard list’ offence in courts
in England and Wales) and Recorded Crime Statistics.
Property crimes
There is no new information available for 2003. Please refer to DrugScope (2001).
Illegal prostitution
There is no new information available for 2003. However, the Home Office will be
releasing a consultation paper in 200472, which will not be in print at the time of this
publication.
Prescription offences
Please refer to MHRA (Medicines and Healthcare products Regulatory Agency) for
further information73.
Violence under the influence
There is no new information available for 2003. The most recent and relevant studies on
this topic are from outside of the UK (Nash Parker and Auerhahn 1998; Erikson 2001).
Driving offences
Please refer to Chapters 6.5.4 and 7.5.1.
8.4 Drug use in prison
In 2003, it was reported that 55 per cent of those entering prison in England and Wales
were problematic drug users (HM Prison Service 2004b).
More detailed information is available only for Scotland who undertake a Reception
Study each year; during one month a random sample of prisoners are tested on
admission to some prisons. The Reception Study was expanded to cover all Scottish
Prison Service establishments in 2003; information from this extended study is not
currently available. Due to the period between last drug use and testing after entry to
prison, urine test results may under report drugs such as heroin. In 2003, 66 per cent of
urine tests were positive for drugs, a fall from 73 per cent in 1998/99. This fall was
reflected in detections of all drugs apart from methadone and Temgesic. Cannabis
(34%), benzodiazepines (30%) and opiates (excluding methadone) (24%) were most
commonly detected (ISD 2004).
71 The Drugs Intervention Programme was originally launched as the Criminal Justice Interventions Programme but
was re-named in October 2004.
72 Please refer to http://www.homeoffice.gov.uk/docs3/paying_the_price.html.
73 This can be accessed through www.mca.gov.uk or www.mrha.gov.uk.
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Since the introduction of Mandatory Drug Testing (MDT) in prisons in England and
Wales, the proportion testing positive for drugs has reduced from 24.4 per cent in
1996/97 to 11.7 per cent in 2003 (HM Prison Service 2004b). In 2002/03, in Scotland,
17 per cent of tests were positive, which has remained unchanged over that past five
years. In Scotland, the drugs most frequently detected were cannabis and opiates, both
12 per cent (ISD 2004).
Research into substance use has been conducted among 301 women in both remand
and sentenced populations across England (Borrill et al. 2003). Eighty-one per cent of
the participants reported having ever used drugs, 77 per cent having ever used
cannabis, and half having used crack, heroin, tranquillisers and amphetamines at some
time. Forty-nine per cent, according to the Severity Dependence Scale (SDS), were
rated as dependent while 31 per cent had injected at some time. White women were
more likely to have a drug use problem than other ethnic groups.
8.5 Social costs
There is no new information available for 2003. Please refer to UK Focal Point (2003)
Chapter 4.3.
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9. Responses to social correlates and consequences
9.1 Overview
As was discussed in Chapter 8.1, drug use can be linked to the characteristics of social
exclusion. The Government set up the Social Exclusion Unit in 1997 and, in addition, the
UK Drug Strategy aims to improve the country’s most deprived neighbourhoods by
raising standards of employment, educational attainment, housing and health, and by
lowering crime rates (Drugs Strategy Directorate 2002a). These are also Government
objectives for UK society in general, so there is a close link between the Strategy and
other central Government initiatives. Several initiatives have come into force that tackle
the issues associated with social exclusion.
Communities Against Drugs (CAD), which ran from 2001/02 to 2003/04, provided
funding to build communities that are resistant to drugs. The work of this initiative has
now been subsumed into a larger generic funding programme, the Building Safer
Communities Programme, administered by the Crime Reduction teams within the
Regional Government Offices to reduce bureaucracy, and give flexibility to local
partnerships to deliver their priorities on crime and drugs.
The Homelessness Directorate, set up in 2002, coordinates homelessness policy
nationally (DTLR 2002), but homelessness issues are also addressed in the UK Drug
Strategy and the Strategy on Rough Sleepers. There has been joint work between the
Homelessness Directorate and the National Treatment Agency for Substance Misuse
(NTA) to build treatment services that are responsive to the needs of the homeless
(Randall et al. 2002). In Scotland, the Homelessness Task Force has responsibility for
improving interventions. 
The progress2work (p2w) programme, initiated in 2002, provides support for clients who
have made sufficient progress in their recovery to be drug free or stabilised, but whose
history of drug use is likely to be a significant factor in preventing them from getting or
keeping a job. Led by the Department of Work and Pensions, it is a cross Government
initiative advised by an inter-departmental group. Representation on the group includes
officials from the Home Office, Prison Service, NTA, Welsh Assembly and Scottish
Executive (see UK Focal Point 2003).
The updated Prison Service Drug Strategy for England and Wales aims to reduce the
supply of illegal drugs into prison through a range of practical initiatives, and to reduce
the demand for drugs amongst prisoners through effective treatment (HM Prison
Service 2002). Initiatives include (HM Prison Service 2004c):
• mandatory drug testing (MDT);
• clinical help with withdrawal, which is available at all local and remand prisons; 
• substitution treatment, which is offered in all female and some male prisons (for 
those on remand or serving a short sentence who have been being maintained on 
methadone in the community, with evidence of current engagement in a 
community programme having been beneficial; for those who are HIV positive 
and/or terminally ill and who are already on methadone maintenance); 
• low threshold counselling, assessment, referral, advice and through-care services 
(CARATs); and
• intensive drug treatment programmes, which are available in some prisons and 
include cognitive-behavioural treatment, 12-Step and Therapeutic Communities 
(TCs).
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9.2 Social re-integration
9.2.1 Housing
Local Authorities introduced the Supporting People Programme in April 2003 as a new
way of funding supported accommodation. It receives more than £25 million (€35.3
million) each year, and is aimed at marginalised groups generally, encompassing drug
users within that client group. 
9.2.2 Education and training
Positive Futures, the national sports-based social inclusion programme for young
people aged 10 to 19 years, offers opportunities to engage in employment, education
and training (see Chapter 3). Research shows that Positive Futures, which operates on
a voluntary basis, has so far attracted nearly 35,000 young people (mostly aged 10 to
16 years). Just under 85 per cent are reported to have developed a meaningful
relationship with the project and have shown encouraging signs of progression. In the
past year, nearly 14,000 young people achieved at least one of the following:
• improving their educational performance;
• undertaking training;
• joining the labour market;
• joining local sports clubs;
• improving their social relations; or
• making personal development progress (Drugs Strategy Directorate 2004c).
9.2.3 Employment
p2w will be rolled out across the UK in 2004. The scheme has already been subject to
an external evaluation by York Consulting74. This initial qualitative study examined the
start up phase of the first pathfinder services and has been used to inform the roll-out
to subsequent districts. A full impact evaluation was planned to begin in 2004 involving
tracking a sample of clients through the whole p2w process. However, the bid for
funding this work has been suspended due to competing analytical priorities. In the
meantime, p2w will be subject to regular (quarterly) performance review drawing on the
regular management information collected from providers by Jobcentre Plus.
Early indications from Jobcentre Plus (2004), who are responsible for the programme,
suggest that interest has been high and that it is successfully helping people recovering
from drug use to get back into the labour market and overcome additional barriers to
work such as a lack of stable accommodation and a criminal record.
9.2.4 School drop out
There is no new data available for 2003. Please refer to Goulden & Sondhi (2001) for
further information.
9.2.5 Financial Problems 
There is no new information available for 2003. Please refer to EIU (2002) for further
information.
9.2.6 Social networks
There is no new information available for 2003. Please refer to NIDA (1998) for further
information.
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74 Please see http://www.yorkconsulting.co.uk/areas_of_expertise_9_employment_progress2work_evaluation.htm for
further information.
9.3 Prevention of drug-related crime
9.3.1 Assistance to drug users in prisons 
Prevention
Drug testing and drug free units 
The target for reducing the proportion of positive results from random MDTs in England
and Wales for 2003/04 to 10 per cent was not achieved: 11.7 per cent tested positive
was achieved, although the overall rate has halved since 1997 when 24.4 per cent
tested positive (HM Prison Service 2004b). Over 28,000 prisoners signed a compact
during 2003/04 for Voluntary Drug Testing (VDT) (HM Prison Service 2004b, 2004c).
The Prison (Amendment) (Northern Ireland) Order 2004, Statutory Instrument 2004 No.
704 (N.I. 5) will allow for mandatory testing for both drugs and alcohol for the first time
in Northern Ireland.
Supply reduction 
A visitor’s ban policy remains in place (banning those who have attempted to bring drugs
into prison). Increased numbers of drug dogs have been made available, as has
provision for closed circuit television (CCTV) in visitor areas. Ongoing work includes a
project on the supply routes and research into electronic drug detection equipment. New
guidance on supply reduction was circulated in November 2003 for England and Wales,
ensuring successful anti-smuggling and detection initiatives are replicated in all prisons,
as well as helping prisons to review performance and develop improvement plans (HM
Prison Service 2004c). 
Harm reduction measures
CARATs are to extend pre-release interventions to include overdose awareness cards
and videos depicting the risks of restarting opiate use.
The Prison Service is exploring ways of making the policy on condom provision clearer
and more uniformly applied. However, at the moment prison health care staff in England
and Wales have been reminded that they should prescribe condoms, where in their
clinical judgement, there is a known risk of HIV infection (CDSC 2003).
There are no present plans to introduce a needle exchange scheme. 
Blood-borne virus testing is provided and a programme of hepatitis B vaccination will be
available in 71 of 137 prisons in England and Wales by the end of 2003 (including all
prisons accommodating young persons). Between January and June 2003, over 6,800
prisoners received at least one dose of hepatitis B vaccine and 3,200 completed a
vaccination course.
Treatment
There are a number of programmes providing assistance to drug users in prisons:
A CARATs review, in England and Wales aimed at delivering a more ‘rounded’ service
began in 2003; the final report is not yet published. The target for CARATs was to have
performed 25,000 assessments in 2004, and this was surpassed with 49,770
undertaken in 2003/04 (HM Prison Service 2004c).
Between 2003 and 2006, healthcare services in all non-private prisons in England will
become part of the National Health Service (NHS). This will mean prison health care is
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75 The Drugs Intervention Programme was originally launched as the Criminal Justice Interventions Programme but
was re-named in October 2004.
financially administered by local health trusts (Primary Care Trusts) and will enhance the
opportunity for linking with a full range of community health service provision.
During 2003/04, prisons offered 60 intensive drug rehabilitation programmes and
Therapeutic Communities (40 cognitive behavioural therapy programmes, 15 ‘12-Step’
programmes and 5 TCs). All drug programmes are to be accredited by the independent
Correctional Services Accreditation Panel by March 2004. However, although the
number of programmes being run has increased considerably, the number of drug users
successfully completing programmes remains small.
In England and Wales, clinical services (detoxification and maintenance-prescribing
programmes) remain available in all local and remand prisons. Clinical management
has continued to grow with nearly 58,000 treatments in 2003/04, 14 per cent more than
the previous year. The majority of interventions were prescribed detoxification regimes.
The Prison Health Department (England and Wales) reviewed its policy towards clinical
management of substance use in light of a number of factors (HM Prison Service
2004d): 
• a growing problem of suicide and self-harm during drug withdrawal;
• management problems during drug withdrawal, including drug smuggling and acts 
of violence towards staff and other prisoners; 
• risk of fatal overdose in the first few days following release from prison;
• the need to provide clinical services in line with the NHS and international good 
practice; and
• in line with the Drugs Intervention Programme (DIP)75, to facilitate continuity of 
treatment for individuals entering prison on a community methadone or 
buprenorphine prescription.
This review has resulted in the drafting of a new clinical model, the principal elements
of which are (HM Prison Service 2004): 
• prescribed management of withdrawal on the first night of custody, informed by the 
reception health-screen and assessment;
• where possible, location of prisoners within a unit that offers access to unrestricted 
24-hour observation;
• for opiate-dependent patients, stabilisation on medication for at least five days 
prior to progression to one of the following treatments: standard detoxification 
(minimum duration of 14 days); extended detoxification (21 or more days) and 
maintenance (up to 13 weeks or beyond, depending on individual need);
• good quality joint working between clinical and CARAT teams;
• joint management and care planning by mental health in-reach services, and 
substance use problems where appropriate;
• ongoing reviews of all extended prescribing regimes, informed by random drug 
tests;
• provision of a 28 day psychosocial programme for all prisoners with problematic 
drug use; and
• all prescribed regimes are to be evidence-based, conforming to Prison Service 
Order 3550 (HM Prison Service 2001) and Department of Health et al. (1999) 
guidelines, and in accordance with the principles of clinical governance.
This model, due for publication in 2004, will bring prison clinical practice in line with
Models of Care (DH 2002b). 
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Withdrawal management units were opened in four prisons (Leeds, Feltham,
Birmingham and Eastwood Park) during 2003. Their enhanced services are to be
evaluated to determine their influence on suicide and self-harm among vulnerable
patient groups.
A national programme of clinical training has been completed, delivered jointly by St
George’s Hospital Medical School in London and Prison Health, across 12 locations to
270 clinicians working in prisons. To build further clinical competence, 30 doctors,
nurses and pharmacists working in prisons were funded for entry into the Royal College
of General Practitioners certificate course in substance use. A new phase of
competence-based education, related to the training needs associated with the current
clinical model, will be introduced in 2005/06.
A low-intensity Short Duration Programme (SDP) delivered to short-term and remand
prisoners will be piloted in 2004. The SDP will provide intensive treatment to adults and
young offenders whose time in prison would previously have precluded them from
accessing intensive drug rehabilitation treatment. It is expected that this programme will
reduce the ‘revolving door’ process (with many short-term prisoners returning to custody
without the opportunity to engage in intensive treatment). 
In Scotland, over 9,000 (67%) new receptions were offered an assessment for help with
substance use; 7,271 (50%) undertook such an assessment (ISD 2004).
Social re-integration
DIP has initiated measures to establish links with services in the community and help
drug-using offenders reintegrate (see Chapter 12).
9.3 2 Alternatives to prison for drug users
In the UK, alternatives to prison for drug users are referred to as non-custodial
responses. DIP was launched in 2003 with the aim of more effectively channelling
problem drug users from the criminal justice system into treatment programmes. Its key
target group is drug-using persistent offenders (See Chapter 12). 
9.3.3 Other interventions for prevention of drug-related crime
Interventions for drug-using young offenders
All Youth Offending Teams (YOTs)76 will, from April 2004, have to ensure all young
offenders are screened for drug use. Those identified with treatment needs will receive
appropriate specialist assessment within five working days, and following assessment,
will receive access to the required early intervention and treatment services within ten
working days.
Driving Offences
The Railways and Transport Safety Act 2003 gives police the power to undertake
preliminary tests of impairment and screening for drugs at the roadside. 
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76 Youth Offending Teams are locally based multi-agency teams set up in every local authority area in England and
Wales to respond to the needs of the young offender in a comprehensive way.
10. Drug markets
10.1 Overview
The latest data about the value of the UK drug market are for 1998 (Bramley-Harker
2001), suggesting a value of around £6.6 billion (€10.4bn). However, this is thought to be
an underestimate and the methodology is being revisited in light of newly available data.
It remains difficult to provide reliable information about the availability and supply of
drugs. Quantities can only be inferred from seizures, other law enforcement
interventions, treatment figures and other data such as deaths. The exact relationship
between supply and demand remains unclear at the macro level; however, widespread
poly-drug use (SWPHO 2002) provides an incentive for traffickers to engage in multi-
drug trafficking (NCIS 2003). A key factor in multi-drug trafficking is the convergence of
the various drug trades, in the Netherlands and Spain, for logistical reasons. Both
countries reluctantly host major foreign and British traffickers, or their representatives
and criminal associates, who broker deals for UK-based groups. Nevertheless, the
largest importers of heroin and cocaine tend to concentrate on a single commodity
(NCIS 2003). These drugs then enter the UK market through a variety of different routes
(see Table 12). 
Table 12: Importation routes of some illegal drugs entering the United Kingdom
Source: National Criminal Intelligence Service 200377.
Information about seizures is provided by the Home Office Research and Statistics
Cocaine Mainly Columbia, Peru
and Bolivia.
Shipped across the Atlantic to
the Iberian Peninsula, the
Netherlands or increasingly to
Central and Eastern Europe.
Shipments are concealed in
heavy goods vehicles and
routed overland to the
Channel and North Sea ports.
It is also smuggled into
the UK by air couriers,
arriving from South and
Central America, and
from the Caribbean.
Crack cocaine It was thought that it
was produced in the
UK in small street-level
quantities but there is
now intelligence that it
is being imported from
the West Indies.
Evidence suggests the
involvement of British
Caucasians, West Africans
and South Asians working
both independently and
collaboratively.
Intelligence indicates
that the UK crack trade
is becoming complex
and dynamic, and that
crack is often sold with
heroin. 
Ecstasy-type
substances
Some ecstasy and
other synthetic drugs
are produced in the
UK.
Ecstasy enters the UK market
from Holland and Belgium
through the ferry ports and
Channel Tunnel.
Ecstasy is exported to
Australia, Malaysia,
South Africa and
locations popular with
British clubbers e.g.
Ibiza.
Heroin Mainly Afghanistan and
the ‘Golden Triangle’.
Much arrives via Northern
Cyprus and Turkey in freight
and passenger vehicles. The
Channel Tunnel and air
couriers are also used.
Drug Origin Importation route Further details
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77 See the National Criminal Intelligence Service website: http://www.ncis.co.uk. 
Directorate who collate figures provided by Customs and Excise, and the police. In
general, seizures of cannabis and crack are increasing. Seizures of LSD are falling
(Ahmad and Mwenda 2004).
Information on the average purity at street level of certain drugs and the content of
tablets is provided by the Forensic Science Service (FSS). The purity of amphetamines,
cocaine and brown heroin has fluctuated over the last few years.
Information on the average price of drugs is provided by the National Criminal
Intelligence Service (NCIS). The prices of ecstasy, heroin and cocaine have been falling
since 1998 although prices of cannabis leaves and resin, amphetamines and crack have
remained largely similar.
Ease of access is often tied closely to patterns and levels of use, where the most
commonly used drugs are usually also the most accessible (Condon and Smith 2003).
10.2 Availability and supply 
10.2.1 Availability of drugs (perceived availability/access in population, other indicators)
There is no new information available for 2003, please refer to UK Focal Point (2003) in
Chapter 10.
10.2.2 Production, sources of supply and trafficking patterns within countries as well as
from and towards other countries
There has been no change in sources of supply and trafficking. Please see Table 12 in
Chapter 10.1.
10.3 Seizures
Latest available information on seizures in the UK is for 2002 (Ahmad and Mwenda
2004). Seizures continued to rise in 2002, by five per cent to a total of 137,304. These
are detailed for each drug in Figure 7, Figure 8 and Table 13. 
Table 13: Number of seizures of illicit drugs made by all law enforcement agencies,
United Kingdom
Source: Corkery and Airs 2001; Ahmad and Mwenda 2004.
Figure 7: Number of seizures of illicit drugs made by all law enforcement agencies,
Drug 2000 2001 2002
Cannabis (total) 93,750 96,460 102,390
Heroin 16,450 18,170 15,360
Cocaine 6,010 6,980 6,630
Crack 2,770 3,690 4,260
Amphetamines 7,080 6,830 6,990
Ecstasy-type 
substances 9,790 10,410 8,300
LSD 300 170 50
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United Kingdom 
Source: Corkery and Airs 2001; Ahmad and Mwenda 2004.
Figure 8: Number of seizures of cannabis made by all law enforcement agencies,
United Kingdom
Source: Corkery and Airs 2001; Ahmad and Mwenda 2004.
10.4 Price/purity
10.4.1 Price of drugs at street level
Generally, in 2003, the average price of illegal drugs continued to fall. However, specific
figures were not available for comment at the time of publishing. Please refer to UK
Focal Point (2003) for the latest available data.
10.4.2 Purity of drugs at street level and composition of drugs/tablets
Trends for 1995 to 2003 are shown in Figure 9. Over the last year, the purity of brown
heroin fell to 33 per cent, cocaine purity increased to 51 per cent, and crack stayed the
same (70% compared to 2002). 
Figure 9: Street level average purity of illegal substances in England and Wales78
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Source: Forensic Science Service (unpublished data).
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78 Note: for cannabis products, the percentage tetrahydrocannabinol (THC) content is shown; for other illicit drugs, the
percentage of pure substance is shown.
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PART B: SELECTED ISSUES
11. Buprenorphine, treatment, misuse and 
prescription practices
11.1. Introduction 
Buprenorphine, an analgesic, is a semi-synthetic derivative of opium, and acts as a
partial agonist at opiod receptor sites in the brain. Methadone and heroin are pure
agonists; they bind to receptors in the nervous system and produce effects such as
euphoria and analgesia, as well as side effects such as respiratory depression.
Antagonists, such as naltrexone and naloxone, can displace agonists and cause
withdrawal symptoms or block the effect of the opiate. Partial agonists such as
buprenorphine can display properties of both. Buprenorphine minimises respiratory
depression and as such has a potential advantage in the prevention of drug-related
deaths due to overdose. However, it can precipitate opiate withdrawals and be injected
(with associated risks).
11.2 Treatment with buprenorphine
11.2.1 Use of buprenorphine 
As a pain reliever, buprenorphine has a long history of use in the United Kingdom. Under
the brand name Temgesic it has been available since 1978, initially in injectable form;
sublingual tablets were introduced in 1982. There has been some evidence of its use in
the treatment of dependence for a number of years in the UK (Donmall et al. 1995), and
is increasingly used for substitution purposes in other countries (Gilvarry and Schifano
2002). 
11.2.2 Licensing 
Buprenorphine was not licensed for use for the management of drug dependence in the
UK until 1999 when the Medicines Control Agency allowed it to be marketed under the
brand name Subutex (a higher dose form than Temgesic), although restricting it to a
Schedule 3 list drug under the Misuse of Drugs Regulations 198579. Such scheduling
requires that relevant restrictions on import, export, production, supply, possession
prescribing and record keeping apply, but all medical practitioners can prescribe this for
treatment. No other product containing buprenorphine is licensed for the management
of opiate dependence.
Buprenorphine remains a Class C controlled drug under the Misuse of Drugs Act 1971
and therefore there are legal penalties for illicit possession and supply.
11.2.3 Guidance
National ‘Clinical Guidelines’ for the management of drug use and dependence, offered
guidance about the use of buprenorphine in the management of withdrawal (DH et al.
1999); maintenance treatment (substitution) with buprenorphine was referred to but little
specific guidance was issued.
73
79 These regulations define the categories of people authorised to possess or supply those drugs controlled under the
Misuse of Drugs Act 1971. Drugs are categorised under a graded scale with drugs such as raw opium, cocaine leaves
and LSD residing in Schedule 1. See http://www.legislation.hmso.gov.uk/si/si2001/20013998.htm for more details. 
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Due to concerns about the possibility of buprenorphine being diverted or misused by
injection80, from 2001 the National Health Service (General Medical Services)
Regulations 199281 were amended to allow doctors to prescribe buprenorphine to be
dispensed by instalments from one prescription (DH 2001b). The product is available in
three strengths, 400 µg (micrograms), two mg (milligrams) and eight mg and each
strength is supplied in packs of either seven or 28 tablets. 
New guidance stated that the only licensed product containing buprenorphine for use in
managing drug dependence is marketed under the brand name “Subutex Sub-lingual
Tablets” (DH 2001b). It is to be used for substitution treatment for opioid dependence in
those aged 16 years and over. It states that supervised consumption should be inherent
to any well-delivered buprenorphine substitution programme and that Temgesic should
not be supplied for substitution treatment of opioid dependence. It is also suggested that
buprenorphine treatment be instigated by specialist practitioners. The Department of
Health is providing the appropriate training in England. The National Assembly for Wales
has introduced a similar change (DH 2001b).
The ‘Clinical Guidelines’ on drug use (DH et al. 1999) advised that locally approved
guidelines for treating drug addiction should be developed for general practitioners
(GPs). As such, a number of health authorities have developed appropriate protocols
and guidance (such as NHS Berkshire 2001). Also, in February 2003, the Royal College
of General Practitioners published guidance and developed a training programme (Ford
et al. 2003). The guidance outlines the indications, contraindications and precautions for
buprenorphine, and examines topics such as dosage regimens, maintenance treatment,
prescribing, detoxification and shared care. It recommends that, initially, buprenorphine
should be dispensed daily and, if possible its consumption should be supervised by a
pharmacist for at least three months. In addition, it emphasises the importance of patient
education. However, the guidance also states that patients who are responding well to
existing treatment (whether buprenorphine or methadone) should remain on their
current treatment.
Further, Ford et al. (2003) state that there appears to be increasing consensus among
clinicians experienced in using both buprenorphine and methadone that: 
• buprenorphine may be better suited to those who wish to cease using heroin, as
the blockade effects of even moderate dose buprenorphine interfere with the
subjective effects of additional heroin use. To achieve the same effect with
methadone, a much higher dose is required. So, those patients who wish to 
continue to use heroin may prefer low dose buprenorphine treatment;
• withdrawal from buprenorphine appears to be milder than from methadone, and 
as such may be preferred for those considering a detoxification program;
• the transition from buprenorphine to naltrexone can be accomplished much earlier 
than that from methadone to naltrexone, and consequently, those considering 
naltrexone treatment may be better suited to buprenorphine.
Ford et al. (2003) then go on to compare buprenorphine to methadone, suggesting that: 
• it is less dangerous in overdose;
• with maintenance doses between eight and 32 µg the effects of other opioids used
‘on top’ are markedly reduced, with optimal effect at a dosage of between 12 to 24 
µg daily;
80 This is a long-recognised problem which had been reported with the prescribing of Temgesic (Pulse 1989). 
81 These regulate the terms under which doctors provide General Medical Services under the National Health Service
Act 1977.
• it is useful in maintenance and detoxification, being easier to withdraw from; and 
• patients report that they remain clearer headed with less ‘clouding’ effect (this may 
be positive or negative for different patients). 
Disadvantages are that:
• it is highly soluble leading to potential for injection;
• it can precipitate acute opiate withdrawal if used incorrectly; and
• it is more expensive than methadone.
11.2.4 Increased use 
Since 2001, with regulations enabling GPs to prescribe buprenorphine more easily,
there has been a considerable increase in the number of prescribed items both in the
management of withdrawal and as a substitute opiate. However, although use of
buprenorphine has significantly increased in recent years (see Table 14), it is still used
much less often than methadone (with 1,614,200 prescriptions being dispensed in
2003).
Table 14: Total prescription items dispensed for Subutex in England
Source: Table compiled by Department of Health 2003.
11.2.5 Cost 
At current prices, the cost of treatment for one year is:
• £1,051 (€1,500) with buprenorphine at 8 µg daily;
• £318 (€450) with methadone mixture at 60 mg daily; 
Given the lack of UK studies and experience, the cost effectiveness of buprenorphine
compared with methadone has not been determined.
11.2.6 Research and reviews in the UK
Recent UK research and reviews suggest that buprenorphine and methadone are of
similar efficacy in retaining clients in treatment and reducing heroin use:  
• a Cochrane Review of buprenorphine maintenance for opioid dependence 
concluded that ‘Buprenorphine is an effective intervention for use in the 
maintenance treatment of heroin dependence, but it is not more effective than 
methadone at adequate dosages’ (Mattick et al. 2004); 
• it has also been suggested that buprenorphine has the potential to ameliorate the 
signs and symptoms of withdrawal from heroin and possibly 
methadone, but treatment protocol and relative effectiveness need to be 
investigated further. It is therefore suggested that there is limited evidence of 
superiority of either medication, and the decision as to which medication to use 
should be made in consultation with each patient after consideration of the relative
merits (Gowing et al. 2004).
In addition, Schering-Plough has recently started the Sirius project. This is a safety
assessment study. The design is observational and it is expected that Subutex and
methadone will be compared in approximately 5,000 patients from 200 treatment
centres (Quartey 2000). 
Prescriptions dispensed Year
1999 2000 2001 2002 2003
Subutex (thousands) 5.132 36.673 75.602 164.27 310.65
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11.3 Misuse of buprenorphine
Gilvarry and Schifano (2003) point out that the very properties, which make
buprenorphine an attractive treatment option (lower dependence, milder withdrawal
symptoms and longer action), also make it attractive to the street market. As a drug of
abuse, buprenorphine has been sniffed, snorted, inhaled, smoked and injected (see
Ghodse 1987). In the late 1980s and early 1990s, a wave of buprenorphine misuse
through injecting was reported in Scotland (Sakol et al. 1989; Morrison 1989;
Hammersley et al. 1990; Lavelle et al. 1991) and to a lesser extent, in the North of
England (Strang 1985; Strang 1991). Abuse was also reported in many European
countries and so in 1989, it became a controlled drug under the Misuse of Drugs Act
1971, following the UN Convention on Narcotic Drugs’ (UNCND) requirement in 1989
that stricter controls be imposed. Subsequently, a significant drop in abuse was reported
(Stewart 1991; Forsyth et al. 1993), although abuse continued in Glasgow until a
voluntary ban on its prescribing to known users by Glasgow GPs in 1992 (Hutchinson
et al. 2000). 
The reporting of buprenorphine abuse is not routinely undertaken in the UK. It is often
listed under the category of ‘other opiates’, except in Scotland, where it can be reported
separately. As a controlled drug, information on seizures by police and HM Customs has
been recorded since 1989, but such information is not routinely published.
Buprenorphine use has been reported in Scottish prisons through mandatory drug
testing (MDT), although since testing began in 1996/97 this has been rare with
approximately 0.01 per cent testing positive in 1999 to 2000 (Table 15).
Table 15: Mandatory drug testing in Scottish prisons: positive tests for buprenorphine
Source: Gilvarry and Schifano 2003.
In England, MDT screening for buprenorphine was introduced in prisons in Yorkshire
and the North East. Corkery reports that between 1 April 2000 and 31 March 2001, 0.2
per cent of all random samples tested positive for buprenorphine (Gilvarry and Schifano
2003). 
Year Number     Positive buprenorphine results 
of tests Number Percentage
1996 to 1997 2,364 71 3
1997 to 1998 7,070 141 2
1998 to 1999 7,162 72 1
1999 to 2000 6,605 66 1
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12. Alternatives to prison targeting for drug-using 
offenders
12.1 Political, organisational and structural information
In the UK, drug treatment cannot be strictly defined as an alternative to custody as if a
custodial sentence is required, offenders will enter custody. However, there is a range
of interventions that seek to increase the number of drug-using offenders accessing
treatment, a key tenet of national drug policy (Drugs Strategy Directorate 2002a).
Policy is coordinated through the Drugs Strategy Directorate in the Home Office. A wide
range of agencies, nationally and locally, cooperate in making treatment accessible to
drug-using offenders (see Chapter 12.2).
12.2 Intervention
Over recent years a number of interventions have been established to provide treatment
to drug-using offenders. 
Arrest Referral 
Arrest Referral involves specialist workers seeing drug-using offenders, usually in police
custody suites and increasingly, in court to provide information and where appropriate,
referral to treatment or other assistance. Involvement is voluntary and it is not an
alternative to prosecution or due process. Schemes have been available across all
police force areas in England and Wales since April 2002. Since 2003, the scheme has
been enhanced in some areas (Enhanced Arrest Referral), extending the role of the
drug worker beyond assessment and referral to include case management (Drugs
Strategy Directorate 2002a).
Drug testing
The Criminal Justice and Court Services Act 2000 includes provision for drug testing on
charge, that is to test for Class A drugs (specifically heroin and crack/cocaine) on:
• those in police detention charged with trigger offences (theft, burglary, robbery and 
other offences under the Theft Act 1968); 
• those in police detention charged with drug offences such as possession and 
supply, if committed in respect of the specified Class A drugs; 
• those at pre-sentence where the court is considering imposing a community 
sentence;
• offenders under probation supervision; or 
• as a condition of release from custody on licence. 
These provisions apply to those aged 18 and over. Drug testing on charge while in
police custody was introduced on a pilot basis in 2001, and is now operational in 114
custody suites in the 66 police areas with the highest levels of acquisitive crime in
England and Wales. From July 2004, the list of trigger offences set out in Schedule 6 of
the Criminal Justice and Court Services Act 2000 was extended to include: handling
stolen goods (under section 22 of the Theft Act 1968); “attempted offences” (under
section 1(1) of the Criminal Attempts Act 1981, if committed in respect of the offences
of theft, robbery, burglary, obtaining property by deception and handling stolen goods);
and offences in relation to begging under sections three and four of the Vagrancy Act
1824. Those charged with non-trigger offences may also be tested, where a police
officer of at least Inspector rank has reasonable grounds to suspect that use of any
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specified Class A drug caused or contributed to the offence and authorises the taking of
a sample.
Conditional Cautioning
Conditional Cautioning targets offenders who admit a first-time minor offence. A caution
can be issued with a condition conducive to restoration or rehabilitation, and the
offender may be prosecuted for the original offence if this is not met. 
Restrictions on bail pilot
A pilot was introduced in May 2004 in Nottingham, Salford and Manchester. This has
given new powers to courts to order drug treatment and assessment as conditions of bail. 
12.2.1 Interventions for drug users under probation supervision
There are a number of interventions with drug users under probation supervision. 
Drug Treatment and Testing Orders (DTTOs)
DTTOs were rolled out to courts in England and Wales in 2000, and parts of Scotland
in 2002. These target persistent offenders who have committed significant numbers of
crimes to fund their drug use. They require the offender to undergo treatment, either in
a residential centre or in the community, for between six months and three years.
Offenders subject to the DTTO are required to undertake treatment and testing as laid
down by a National Standard. Failure to comply results in enforcement measures which
can lead to breach and subsequent revocation of the order and re-sentencing.
Additionally, in English and Welsh law, the courts have a formal role in the reviewing
process. Under the Criminal Justice Act 2003, DTTOs will be replaced with community
sentencing options which will be easier to match to individual circumstances. 
General rehabilitation interventions
These are largely provided as part of a Community Rehabilitation Order (CRO) or
Community Punishment and Rehabilitation Order (CPRO). Interventions include support
into detoxification and therapeutic “lifestyle” services such as acupuncture and
counselling. They are voluntary on the part of the offender.
Accredited substance misuse programmes
Addressing Substance Related Offending (ASRO) and the Programme for Reducing
Individual Substance Misuse (PRISM) provide a structured environment for the delivery
of group or one to one programmes aimed at assisting offenders to address their drug
use but do not include any element of clinical intervention. These are most commonly
delivered as a requirement of a CRO, CPRO or DTTO.
CROs or CPROs with ASRO are targeted at offenders for whom both drug use and
offending is an issue, but who are fairly stable and have no clinical treatment needs.
ASRO and PRISM have currently been adopted by around half of the 42 probation
areas in England and Wales. The theoretical and evidence base for ASRO and PRISM
can be found in their respective theory manuals (McMurran and Priestly 2000; Priestly
and McMurran 2000). Results of a research evaluation are due to be reported in
October 2004.
The Offender Substance Abuse Prevention Programme (OSAPP)
OSAPP was piloted in 2003 (National Probation Service for England and Wales 2003)
and is being rolled out to the remaining probation areas. The programme is based on a
cognitive behavioural model. 
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Drug Abstinence Orders (DAOs)
DAOs are aimed at those whose offending and drug use is at a fairly low level, without
additional offending behaviour problems.
Drug Abstinence Requirements (DARs)
DARs target offenders who are dependent on or have a propensity to use drugs, and
where there is no immediate need or willingness for treatment although they are
assessed as requiring some form of behavioural intervention to address their offending
behaviour.
Generic Community Sentencing is being established, which will allow magistrates to
select from a range of options, including a drug rehabilitation requirement (which will
supersede DTTOs, DAOs and DARs) and to tailor community sentencing to the needs
and profiles of individual offenders.
The Drugs Intervention Programme
In 2003 the Drugs Intervention Programme (DIP)82 was launched as a critical part of the
Government’s strategy for tackling drugs. It is a three-year programme to develop and
integrate measures for directing adult drug-using offenders out of crime and into
treatment. The programme seeks to take advantage of all opportunities to identify drug-
using offenders within the criminal justice system (those in police custody, with the
courts, on probation and in prison), not only engaging them in treatment, but using a
case management approach to integrate and co-ordinate treatment and care. Beyond
the initial programme, it is envisaged that these processes will become the normal way
of working with drug-using offenders across England and Wales. The £447 million (€630
million) programme draws together and builds on the best existing solutions available
(identified above) and introduces new elements, such as throughcare and aftercare. Key
partners to the Home Office are criminal justice agencies such as the police, prisons,
probation officers and the courts, along with the Department of Health, the National
Treatment Agency for Substance Misuse, treatment service providers and those who
provide linked services such as housing and job-seeker support. 
Delivery of the programme at the local level is through Criminal Justice Integrated
Teams (CJITs). The CJIT allocates a worker after a drug-using offender has been
assessed and it has been agreed that he/she will be taken onto the CJIT caseload. This
can occur at any point in the criminal justice system or on leaving treatment. The CJIT
worker will develop a care plan with the offender and link with appropriate interventions.
Where a CJIT client is remanded into custody, CARATs (see Chapter 9) take
responsibility for managing drug treatment whilst the offender is in prison and liaise with
the CJIT in preparing release plans at the end of the sentence.
Aftercare arrangements will also be made, providing support after the offender reaches
the end of a prison based treatment programme, completes a community sentence or
leaves treatment. These include access to additional support such as housing,
managing finance, family issues, learning new skills and employment.
A national framework has been developed to manage the transfer of information
between community services (CJIT) and the Prison Service, and between the
community and the Probation Service. 
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82 The Drugs Intervention Programme was originally launched as the Criminal Justice Interventions Programme but
was re-named in October 2004.
In the first year, 2003/04, the programme rolled out its various components in 25 Drug
(and Alcohol) Action Teams (D(A)ATs) areas across England which cover 30 police
Basic Command Units83 with high levels of acquisitive crime. From April 2004, funding
for throughcare and aftercare will be available to all D(A)ATs and partnerships across
England and Wales, ensuring access to, and co-ordination of, appropriate aftercare
arrangements to provide those leaving the criminal justice system or treatment
programmes with continuity and vital support at the time when they are most vulnerable.
In April 2004, the intensive programme will be extended to a further 36 Basic Command
Units, and a further expansion is planned for 2005/06.
12.2.2 Young offenders
DIP is currently implementing special measures for those under 18 years to reduce the
risk of continued offending behaviour. Key partners to this work are the Youth Justice
Board, the police, D(A)ATs, Youth Services, Connexions, the National Treatment Agency
for Substance Misuse, voluntary agencies, and other child-centred services. (See
Chapter 1 for details regarding the national co-ordination of drugs policy.)
Arrest Referral schemes and drug testing on charge (see Chapter 1.1), which are
dedicated to targeting drug-using offenders who are under 18 years, have been
established in ten pilot areas for the first time. Each stage of the schemes provides an
opportunity to identify children and young people who have, or are at risk of developing,
problems with drugs, assess their needs and direct them to appropriate support and
treatment services (Home Office 2004b). Taken together and with other services outside
the scope of DIP, they deliver an end-to-end programme of support to young people at
each stage of the criminal justice system.
12.3 Quality assurance 
12.3.1 Guidelines 
Guidance is available for a number of the interventions (DPAS 1999a; DPAS 1999b;
Drugs Strategy Directorate 2003b).
12.3.2 Evaluation and research 
The majority of evaluation programmes on criminal justice system interventions with
drug-using offenders (such as Home Office 2004c) use the following indicators to
evaluate success: 
• levels of treatment uptake and retention;
• levels of drug consumption;
• rates of re-offending (measured variously through levels of re-arrest, reconviction 
or self-reported re-offending, depending on the individual evaluation); and 
• where possible, whether there have been any improvements in health and social 
welfare. 
Data systems for analysing activity and outcomes are still under development. However,
some information is available. By April 2004 approximately 5,000 offenders (25% being
persistent offenders) per month were being drug tested, of whom, half were testing
positive for Class A drugs (Home Office 2004c). Evidence from pilots suggests wide
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83 This refers to a specific part of the police force in England and Wales. Basic Command Units are headed
by a police superintendent and serve an average population of 166,000 people. Most are coterminous
with the boundaries of one or more local authority area. For further details, please see
http://www.policereform.gov.uk/whitepaper/chapter4/4.3.html. 
variation in the extent and nature of drug use among the population charged for
acquisitive crime.
A number of factors critical to the successful implementation of drug testing on charge
were identified. These included: strong leadership; good working relations across
different stakeholders; a clear vision; clear accountability mechanisms; and structures to
monitor and improve performance as required (Nacro and DrugScope 2003). 
The number of drug-using offenders in treatment is increasing; there has been a 47 per
cent increase in numbers starting treatment in DIP areas in 2003, while waiting times for
treatment in the ‘intensive’ DIP areas have fallen significantly (Home Office, personal
communication). 
Cluster analysis identified two main groups among the population receiving DAOs and
DARs attached to a CRO:
• individuals with recent multiple drug use (mainly both heroin and crack), high levels
of recent and previous offending, high incidence of previous links with treatment
and high levels of drug-related problems. Most had strong social networks with
other drug users and the vast majority believed that their offending was linked to
their drug use; and 
• individuals with lower levels of recent drug use and considerably lower rates of
previous offending. Though they also commonly reported drug-related problems,
they were far less likely than to link their offending with their drug use. (Matrix
Research and Consultancy and NACRO 2004).
Some, albeit limited, comparisons have been made between those entering treatment
through conventional routes and Arrest Referral. They suggest that those entering
through Arrest Referral are likely to be a ‘harder to help’ group of more chaotic drug
users with considerably higher levels of offending. There were also lower levels of
retention and completion among the Arrest-Referred group than those conventionally
referred (Sondhi et al. 2002). This suggests a need for greater support during and after
treatment for the criminal justice-referred group. The Home Office is currently
considering research into variations of treatment outcomes, which among other things
would examine outcomes by referral source.
Evidence from the evaluations of Arrest Referral, DTTOs and drug testing in the criminal
justice system has identified substantial reductions in the extent of offending, illegal
drugs spending and drug consumption. Among the DTTO client group:
• the number of crimes committed by offenders fell from an average of 137 offences
in the month before arrest to around 34 per month (a reduction of 75%) after only
six weeks on the order; and
• the average amount spent on drugs fell from £400 (€568) per week in the four
weeks before arrest to £25 (€35) per week in the first four to six weeks of the Order
(Turnbull et al. 2000).
The follow-up two-year reconviction study found that 53 per cent of those who
completed their order (30% did this) were convicted of a crime within two years of the
start of their sentence, compared with 91 per cent of those whose orders were revoked. 
The report concluded that the key to success in DTTOs lies in retention, as well as:
strong inter-agency and partnership working; appropriate staffing at all levels; improved
referral and assessment; effective monitoring and review of offenders (through testing
and court reviews); and streamlining breach procedures (Turnbull et al. 2003).
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Among Arrest Referral clients, 67 per cent were arrested less often following referral and
self-reported offending was substantially reduced. Factors identified as contributing to
the success of schemes include: reduced waiting times for treatment, catering for the
different needs of clients, and a good relationship between Arrest Referral and treatment
providers (Sondhi et al. 2002). 
Among those receiving a DAO or DAR, arrests, convictions and imprisonment were all
lower for the pilot group in contrast to the comparison group who received standard
community sentences. However, this was not statistically significant. 
Individuals tested on licence or under notice of supervision, at around four months after
testing started, were less likely to have been arrested (38%) or convicted of an offence
(20%, both with a sample size of 829) than those in the comparison group on licence
without a drug testing condition (65% and 39% respectively, with a sample size of 198)
(Matrix Research and Consultancy and NACRO 2004).
12.3.3 Training for staff 
See Chapters 5.2.4, 5.3 and 9.2.2. 
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13. Public nuisance: definitions, trends in policies, 
legal issues and intervention strategies
13.1 Definition
Public nuisance is a matter of perception and it is not easy to categorise nationally what
all citizens consider to be nuisance behaviour. The Crime and Disorder Act, 1998
formally defines it as acting “in a manner that caused or was likely to cause harassment,
alarm or distress to one or more persons not of the same household as [the defendant]”.
Public surveys on crime and policing in the UK suggest the public place a high priority
on tackling incidents described as anti-social behaviour, minor disorder or ‘quality of life
issues’. The following types of behaviour, incidents and complaints are examples
(Lupton et al. 2002; Thorpe et al. 2004): 
• noise;
• using and selling drugs;
• unkempt gardens (e.g. those which attract dumping of goods, creating ‘eyesores’);
• alcohol and solvent abuse;
• criminal behaviour;
• prostitution;
• verbal abuse;
• uncontrolled pets and animals;
• intimidating gatherings of young people in public places;
• harassment (including racist and homophobic incidents);
• damage to property (including graffiti and vandalism);
• intimidation;
• nuisance from vehicles (including parking and abandonment);
• nuisance from business use;
• rubbish dumping and misuse of communal areas;
• riding/cycling on footpaths; and 
• aggressive begging.
Some are criminal, whilst others are not. They highlight the fact that such types of
behaviour do not fall into the ambit of one agency, and that there is a need to work
constructively with local communities to identify local problems of anti-social behaviour
and develop appropriate strategies to tackle them.
At one level, all drug problems can be considered to be public nuisance. However, the
Home Office suggests the following constitute public drug-related nuisance as they
involve an aspect of visible, or street-based disturbance that has negative impacts
beyond users and their immediate families, and which can blight locations: 
• public drug taking and visible drug-related intoxication;
• drug-related litter;
• visible drug-related behaviour – sex workers, begging, street homelessness;
• the sale of drugs in public settings, especially to young people;
• the sale of drugs from residential or other property; and 
• drug-related street crime, where it is clear that drugs are the cause of the crime.
This categorisation is indicative rather than definitive, but it highlights the priorities for
action in the UK. All illegal substances are covered by this categorisation.
With European partners, through the Pompidou group, the UK has been working to
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develop a consensus opinion on what constitutes public nuisance about drugs and to
share practice between states on effective forms of interventions that could minimise the
harm from such settings.
13.2 Tackling ‘Public Nuisance’
As the problem of nuisance includes so many different types of behaviours, the range
of responses is equally broad.
UK policy seeks to help persons who cause street problems and community disorder
through their drug use by directing them into treatment and to safer methods of using
whilst they develop control (see Chapter 12). criminal justice and situational control
methods take a different approach through controlling unacceptable behaviour, street
management systems, criminal justice responses and control strategies for the public
space, as it is about offering treatment. Tackling ‘public nuisance’ involves a variety of
specialists including drug specialists and police working in partnerships.
13.3 Genesis
The Drugs Strategy Directorate works with the Anti-Social Behaviour Unit to tackle drug-
related anti-social behaviour and public nuisance84. A combined programme of work
between the Home Office and the Office of the Deputy Prime Minister, and involving the
Department of Health, focuses on the most manifest forms of drug use as they affect
British communities. A number of research initiatives have been funded concerned with
local drug markets and how they affect local communities (Lupton et al. 2002). 
13.4 Measures taken
Building ‘bottom-up’ community responses to drugs is a major strand in drug policy
(Drugs Strategy Directorate 2002a). As such, local Drug (and Alcohol) Action Teams
(D(A)ATs), working with Crime and Disorder Reduction Partnerships, seek to provide a
balance between treatment and enforcement. As part of this, Communities Against
Drugs (CAD) (2001-2003) enabled many community groups and organisations to
engage in developing innovative responses to their local problems (see Chapter 3).
Funding through the CAD programme has helped to focus the work of local partnerships
on developing strategies to address street drug use problems. 
The Home Office has published a number of guidance manuals to local partnerships
who manage such problems85. These are concerned with: street homelessness
(Randall et al. 2002); regeneration and deprived areas (Home Office 2002); dance clubs
and venues (Webster et al. 2002); street crack markets (Burgess et al. 2003); housing
management settings (Drugs Strategy Directorate 2004d); tackling street prostitution
(Hester and Westmarland 2004; Hunter et al. May 2004); and begging (Drugs Strategy
Directorate 2004a). All recommend an approach comprising a mixture of enforcement,
treatment and support. Action also includes work to regulate street environments to stop
such problems occurring in the future. For example, one project will tackle drug-related
litter through educating the general public, users and those who supply needles.
84
84 The anti-social behaviour website can be found at
http://www.homeoffice.gov.uk/crime/antisocialbehaviour/index.html. 
85 The crime reduction toolkit is available at http://www.crimereduction.gov.uk/toolkits/as03.htm. 
The Anti-Social Behaviour Act 2003 will tackle a problem which has emerged over the
past few years: properties used for the sale and use of crack and other Class A drugs,
which are associated with serious nuisance. The Act is part of both (a) the national
strategy on anti-social behaviour, which extends more widely than drug-related
behaviour86 and (b) the national crack strategy (Drugs Strategy Directorate 2002b), a
component of the Drug Strategy. The Act makes an explicit link, for the first time,
between penalties and powers to control drug-related behaviour with nuisance arising
from them. Previously the only punishable act was that of possessing or supplying (or
producing or trafficking etc.) the drug itself. The new Act criminalises subsequent
nuisance associated with such offences. Its powers are targeted against properties, not
people, as it enables the closure of premises used in connection with the production,
supply or use of Class A drugs and which are associated with disorder or serious
nuisance. The Act also contains other powers against nuisance, none of which are
defined as drug-related even though they may be caused by drug use. Guidance to the
police and courts has been produced by the Drugs Strategy Directorate (2004e). 
In addition, a new plan for the police published in the spring of 2004 defines the way
police forces should take account of drug-related nuisance (Home Office 2004d). This
requires the police to meet certain key objectives: to reduce crime, and to tackle
criminality, anti-social behaviour and the fear of crime. In tackling anti-social behaviour
and disorder, Chief Officers and police authorities are expected to include in their local
plans a strategy for tackling youth nuisance and anti-social behaviour. In formulating and
implementing this, forces are to work closely with Crime and Disorder Reduction
Partnerships and to make best use of all the available tools including Anti-Social
Behaviour Orders (ASBOs), Anti-Social Behaviour Contracts, fixed-penalty notices, the
power to seize vehicles being used in a manner causing alarm and the power to take
action against badly run pubs and clubs. In reducing the volume of crime, street crime,
drug-related crime, violent crime and gun crime in line with local and national targets,
local police plans are expected to identify how forces and authorities will contribute to
crime reduction, both through their own efforts and by working in partnership with other
agencies, and set appropriate local targets. Local plans must also include local three-
year targets for reducing vehicle crime, burglary and robbery. 
13.5 Results/evaluation
Policy is always kept under review. The Home Office is developing recording systems
to measure the use of the closure powers for ‘crack’ houses.
85
86 For further information see http://www.together.gov.uk.
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